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ABSTRACT 
 
 
KYLE JAMES THOMPSON.  Effects of S-adenosyl-L-methionine on collagen 
expression in activated hepatic stellate cells.  (Under the direction of DR. LAURA W. 
SCHRUM) 
 
 
 Liver fibrosis is defined as the excessive accumulation of extracellular matrix 
(ECM) components, which can disrupt the normal liver microcirculation and lead to 
injury.  Unresolved, hepatic fibrosis can progress to cirrhosis, an end-state liver disease.  
Hepatic stellate cells (HSCs) are the chief mediator of fibrosis in the liver.  Normal HSCs 
are quiescent, store vitamin A, and regulate sinusoidal blood flow.  Upon a noxious 
stimulus, HSCs transdifferentiate into a myofibroblast-like cell, proliferate, migrate to the 
site of injury, and secrete ECM components, in particular type I collagen.  The 
antioxidant S-adenosyl-L-methionine (SAMe) was evaluated as a therapeutic agent for 
the modulation of type I collagen in activated HSCs.  Treatment with SAMe resulted in a 
91% reduction in type I collagen secretion, however there was no significant change in 
intracellular collagen protein or mRNA expression.  SAMe also increased NF-κB 
activity, a redox-sensitive transcription factor.  Blocking NF-κB with a dominant-
negative form of IκBα abolished SAMe-mediated type I collagen inhibition in Rat-1 
fibroblasts.  Examination of post-transcriptional fate of procollagen mRNAs revealed 
polyubiquitination of intracellular type I collagen following administration of SAMe.  
The endoplasmic reticulum (ER) proteins Grp78 and protein disulfide isomerase (PDI) 
were also significantly decreased by SAMe following 24 hours of treatment.  These 
findings may represent a novel mechanism for modulating type I collagen expression in 
activated HSCs.  We also report the development of a “two-hit” model of hepatic fibrosis, 
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utilizing the Lieber-DeCarli liquid ethanol diet with concomitant injections of 0.5 mg/kg 
LPS semi-weekly.  After 8 weeks of ethanol and LPS, animals developed significant 
perivenular and perisinusoidal fibrosis.  Treatment with 10 mg/kg of SAMe daily 
abolished ethanol and LPS-induced fibrosis with a decrease in oxidative stress, and 
expression of TGF-β and the downstream signaling molecule Smad3.  SAMe also 
attenuated established hepatic fibrosis in a BDL model.  These findings suggest SAMe is 
effective as both a preventative and curative treatment for hepatic fibrosis, and our “two-
hit” model of ethanol feeding with LPS administration is appropriate for investigating 
liver fibrosis. 
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CHAPTER 1: INTRODUCTION 
 
 
Liver Fibrosis 
 Liver fibrosis is an exacerbation of the generic wound-healing process of the liver 
and is defined by excess synthesis and deposition of extracellular matrix (ECM)
components [1].  The accumulation of ECM in the sub-endothelial space of Disse can 
disrupt the microcirculation of the liver leading to the damage and death of parenchymal 
cells (hepatocytes) [2].  Liver fibrosis is a major contributor of morbidity and mortality, 
as unresolved fibrosis may progress to cirrhosis and result in organ failure or progression 
to hepatocellular carcinoma (HCC) [3].   
 Cirrhosis is the end stage consequence of extended fibrosis, resulting in extensiv  
scarring of the liver, dysfunction of the parenchyma, and ultimately death.  
Complications of cirrhosis include ascites, renal insufficiency, hepatic encephalopathy, 
and esophageal varicies [4].  Worldwide, cirrhosis is a significant cause of death with an 
estimated 786,483 fatalities attributed to the disease in 2002 according to the World 
Health Organization.  This number is increased when factoring in deaths due to HCC, of 
which up to 80% of the cases have an underlying presence of cirrhosis worldwide [3].  In 
the United States, cirrhosis is the 12th leading cause of death, with 27,530 fatalities in 
2005 according to the Centers for Disease Control.   
 Hepatic fibrosis is a common sequela for a variety of insults such as industrial 
solvent exposure, autoimmunity, cholestasis, in-born errors of metabolism, viral 
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infection, and ethanol abuse.  Nonalcoholic steatohepatitis (NASH) has also been 
recently as a major cause of liver fibrosis [5].  Worldwide the primary cause of hepatic 
fibrosis is Hepatitis C infection.  In the Western Hemisphere, however, chronic ethanol 
consumption is the principal cause of liver fibrosis; 44% of end-stage liver disease cases 
in the United States are associated with excessive ethanol consumption.  Clinical 
intervention is limited by the presentation of disease; as many as 40% of patients with 
cirrhosis are asymptomatic [6].  However, deterioration of the liver progresses rapidly as 
complications such as encephalopathy and esophageal varicies arise with patients 
experiencing 50% mortality over 5 years.   
The principal therapeutic resolution of cirrhosis is orthotopic liver transplantatio .  
Unfortunately this course is limited by the availability of suitable organs for transplant.  
In 2006, there were 6,227 liver transplants performed in the United States.  However, at 
year-end, 16,937 persons remained on the waiting list for transplantation according to the 
Organ Procurement and Treatment Network.  Furthermore, not all individuals with end-
stage hepatic disease are suitable candidates for transplantation.  Thus, developm nt of 
therapeutic strategies to prevent or reverse the progression of liver fibrosis to cirrhosis, in 
addition to prolonging the survival of patients with cirrhosis, remains of great interest.  
Additionally, accumulating findings suggest there may be reversibility of cirrhosis with 
resolution linked to removal of the underlying disease.  Animal studies utilizing rodents 
treated with the hepatotoxin, carbon tetrachloride, followed by 4 weeks of recovery 
showed recovery of fibrosis.  Similar studies using a bile duct ligation model of fibrosis 
and cirrhosis resolves following surgical biliojejunal anastomosis [7, 8].  In humans, 
evidence of regression of fibrosis or cirrhosis based on serial liver biopsies has been seen 
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in individuals with autoimmune hepatitis controlled by immunosuppression, viral 
hepatitis responsive to antiviral therapies, and biliary stasis caused by chronic pancreatitis 
or common bile duct stenosis corrected with adequate treatment [9-12]. 
The histological features of the scar tissue seen in cirrhosis are identical 
regardless of the etiology of the disease.  However, the location of initial scarring often 
differs and its location can be attributed to both the underlying etiology and subsequent 
prognosis.  Pericentral fibrosis (zone 3) (Fig. 1) is a common feature in alcoholic fibrosis, 
whereas in contrast, viral hepatitis typically results in periportal fibrosis (zone 1) [6].  
These findings are not trivial as zone 3 fibrosis confers a higher likelihood to progress to 
severe fibrosis.  The principle tool to diagnose liver fibrosis is liver biopsy.  This is an 
invasive procedure that commonly results in pain and occasionally major complications 
for patients [13].  The heterogeneous distribution of fibrosis in the liver has also led t  
sampling error (a liver biopsy represents approximately 1/50000th of human liver mass) 
of 15-25% of cases utilizing liver biopsies [14].  These pitfalls associated wih liver 
biopsy as a diagnostic tool has led to efforts to develop novel identifiers of liver fibrosis.  
Many investigators have attempted to use a panel of biochemical and hematologic l 
markers to develop indices for the diagnosis of hepatic fibrosis, such as the proprietary 
algorithm derived from five biochemical variables and marketed as Fibrotest [15].  Other 
efforts have focused on noninvasive radiological techniques to diagnose liver fibrosis.  
One promising technique utilizes magnetic resonance elastography to calculate iver 
stiffness, a condition directly correlated with extent of hepatic fibrosis [16].   
The fibrotic scar is comprised primarily of fibrillar collagens such as type I (a 
repeating heterotrimer of two α1(I) and one α2(I) polypeptide strands) and III, in contrast 
4 
 
to type IV collagen of the basement membrane.  Accumulation occurs due to a net 
increase in deposition of ECM components; either through their synthesis or a decrease in 
degradation by matrix metalloproteinases (MMPs). Although the cirrhotic bands 
surrounding regenerative nodules are the most recognizable form of scarring, it is the 
deposition of ECM in the space of Disse leading to the disruption of hepatic 
microcirculation and diminished nutrient delivery to the parenchyma responsible for 
injury. 
The liver is composed of four primary cell types: the hepatocytes, which are 
responsible for the majority of hepatic functions; endothelial cells which form the lumen 
of hepatic capillaries or sinusoids; Kupffer cells, which are the resident macrophages of 
the liver and reside within the sinusoid; and hepatic stellate cells (HSCs) located in the 
space of Disse between the parenchyma and the sinusoidal endothelium (Fig. 2). The 
cellular basis of hepatic fibrosis has long been debated with early focus on parenchymal 
cells of the liver.  However, the development of procedures to isolate purified populatins 
of nonparenchymal cells in the liver led to the identification of the HSCs as a principle 
source of collagens in fibrosis [17, 18].  This led to the realization that collagen 
production in previous isolates of hepatocytes were most probably due to contaminating 
HSCs [19].  Evidence has emerged supporting several distinct cell populations capable of 
producing collagens during hepatic fibrosis besides HSCs.  Hepatic myofibroblasts 
capable of matrix production have been shown to emerge from fibroblasts residing withi  
the portal connective tissue, perivascular fibroblasts associated with the portal and central 
veins, and periductular fibroblasts residing along bile duct epithelial cells [20-23].  
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Additional studies have suggested a substantial proportion of myofibroblasts in human 
hepatic fibrosis are of bone marrow origin [24]. 
Animal Models of Liver Fibrosis 
 Numerous animal models exist which permit the investigation of the underlying 
mechanism of hepatic fibrosis as well as examining the efficacy of potential treatments.  
Foremost are those most clinically relevant to the progression and presentation of liver 
fibrosis in humans.  However, because of the varying success and ease of implementing 
these animal models, much attention is currently being paid to improving existing models 
and developing newer models of fibrosis.   
 Bile duct ligation (BDL) is a model often employed in rodents to establish 
cholestasis which can result in periportal fibrosis in 7 to 14 days.  Through ligature of the 
common bile duct, stagnation of bile flow occurs resulting in jaundice due to the 
accumulation of conjugated bilirubin [25].  The blockage of free bile flow causes injury
to hepatocyte membranes due to the strong detergent action of hydrophobic bile acids 
[25].  BDL also induces biliary epithelial and oval cell proliferation leading to the 
formation of new bile ductules [26].  Associated with hepatocyte death is inflammation 
often attributed to the accumulation of neutrophils, however it remains unclear the role 
played in the initiation and progression of fibrosis [27, 28].   
 The kinetics of events associated with BDL-mediated injury have been 
characterized in rats by Georgiev et al [29].  Following ligation of the common bile duct, 
there is an acute elevation of serum alanine transaminase (ALT), a serum ma ker often 
associated with liver damage, peaking at day 2, followed by a rapid decline at day 3 
although remaining chronically elevated.  This finding coincides with a peak in the
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presence of biliary infarcts (areas of focal hepatocyte necrosis) at day 2, with few infarcts 
detectable in subsequent days.  Concomitant with focal necrosis is a peak of transf rming 
growth factor-alpha and hepatocyte growth factor, key cytokines in the initiation of 
hepatic regeneration.  Following initiation of regeneration there is a peak at day 5 of 
Ki67+ hepatocytes, a marker of proliferation.  An examination of key mediators of 
fibrosis revealed increase levels of tissue inhibitor of metalloproteinase (TIMP)-1, 
transforming growth factor-beta (TGF-β), and α1(I) collagen peaking at day 3, followed 
by a second peak for TIMP-1 at day 7 and day 14 for TGF- β and α1(I) collagen. 
 Although BDL is a well-characterized and reproducible method of introducing 
hepatic fibrosis, the model has several limitations.  The technique requires an nvasive 
survival surgery requiring well-trained staff and can lead to complications that may result 
in animal loss. BDL also represents a progression of fibrosis not commonly seen in th  
majority of human individuals with fibrosis as the fibrosis is periportal (zone 1) (Fig. 1) 
in nature. 
 Another frequently utilized animal model of fibrosis in rodents is treatment with 
the industrial solvent carbon tetrachloride (CCl4).  CCl4 administration has the advantage 
of being a well-characterized and reproducible model that can be delivered by a variety of 
minimally-invasive routes such as intraperitoneal (i.p.) injection, oral gavage, and 
inhalation [30].  CCl4 causes injury via its metabolism by hepatic oxidases to yield a 
trichloromethyl radical which in turn initiates lipid peroxidation and may also interact 
with proteins containing sulphydryl groups [31, 32].   
 CCl4 administration induces zone 3 necrosis, apoptosis of hepatocytes, 
inflammation, and activation of HSCs.  With repeated dosing, CCl4 can be used to induce 
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bridging fibrosis (4 weeks), where fibrosis spreads to link the portal tract and central vein 
radicle, cirrhosis (8 weeks), and advanced cirrhosis with micronodule formation (12 
weeks) [31].    
 Due to the high prevalence of alcoholic liver disease (ALD) in the Western 
Hemisphere there is an interest in developing animal models of ethanol-induced liver 
fibrosis or cirrhosis.  To date a number of models have been developed with varying 
degrees of success in reproducing the features of ALD.  There remains, however, a need 
to develop a clinically-relevant model of ethanol-induced liver fibrosis that produces the 
classic pattern of alcoholic hepatitis in humans and is readily accessible to inv stigators. 
 The most widely-used method of feeding ethanol to rodents is the Lieber-DeCarli 
(LD) liquid ethanol diet.  Ethanol is delivered by a calorically- and nutritionally-complete 
diet with 36% of the calories provided by ethanol [33].  L-D liquid ethanol diet 
administration causes pronounced steatosis and apoptosis within 4 weeks; however, there 
is an absence of inflammation and fibrosis [34].  Thus, it was postulated that in rodents 
on liquid ethanol diets that a secondary stress was needed to induce fibrosis.  Studies 
using the L-D diet with a substitution of calorie source (high fat, low carbohydrates) 
resulted in mild fibrosis and extensive steatosis [35].  More dramatic fibrosis wa  induced 
with the addition of high levels of Vitamin A to the L-D, diet whereas simple Vitamin A 
administration alone did not cause injury [36, 37].   
 Although the L-D diet alone does not result in hepatic fibrosis in rodents, it 
remains a valuable tool for ethanol feeding in rodents.  It is a non-invasive method to 
deliver ethanol that overcomes the natural aversion to ethanol that rodents possess [38].  
The model also allows for the easy manipulation of the dietary conditions in the addition 
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of secondary stresses to better establish a reproducible model of fibrosis that is relevant to 
human pathology. 
 Another model of delivering ethanol to rodents is the Tsukamoto-French Model 
of Alcoholic Liver Injury (TFMELD).  Using an intragastric tube, ethanol can be 
constantly infused into the stomachs of rodents, allowing for the maintenance of 
consistent levels of ethanol.  TFMELD alone does not induce cirrhosis; however, a rapid
fibrosis, and subsequent cirrhosis, occurs when ethanol is supplemented with a carbonyl 
iron source [39, 40].  Use of TFMELD by investigators is limited as the model requires 
the long-term placement of a gastric feeding tube into the stomachs of rodents, requiring 
skilled staff to place and maintain the feeding tube.  The model is also limited as it oes 
not represent the normal route of ethanol consumption in humans.  
Hepatic Stellate Cells 
 The response to injury in hepatic fibrosis involves several cell types in the liver, 
as well as the involvement of infiltrating cells such as neutrophils and macrophages.  
However, HSCs are directly responsible for the majority of the synthesis and 
accumulation of ECM components, particularly type I collagen [18].  Despite this active 
role in liver fibrosis, HSCs have several important functions including retinoid storage 
and metabolism, secretion of growth factors and cytokines, maintenance of the ECM via 
production of its components (in the normal liver, typically type IV collagen) and MMPs, 
and regulation of sinusoidal perfusion by virtue of the contraction and relaxation of HSCs 
in response to vasoactive substances [41].   
 The embryonic origin of HSCs has been the focus of much controversy as 
extensive efforts have yet to yield a definitive answer.  Several hypotheses ave been 
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suggested as to the origin of HSCs: septum transversum mesenchyme, mesothelial cells 
lining Glisson’s capsule on the liver’s surface, neural crest, and endoderm [42, 43].  
HSCs are known to express a number of neural markers such as reelin, nestin, neural cell 
adhesion molecule, glial-fibrillary acidic protein, and receptors for neurotransmitters [44-
47].  However, the likelihood of a neural crest origin of HSCs was diminished by a study 
utilizing double transgenic mice possessing a transgene encoding Wnt-1-Cre (Cre 
recombinase) and a second transgene, encoding yellow fluorescent protein (YFP) floxed 
(flanked by loxP) by a stop cassette.  In this system, cells expressing Wnt-1 would also 
produce Cre.  Cre catalyzes site-specific recombination of DNA between loxP sites.  
Because all known cells derived from neural crest express Wnt-1, utilizing these 
transgenic mice, the stop cassette preventing transcription of the YFP gene would be 
removed in neural crest-derived cells allowing expression (Fig. 3) [48, 49].  All known 
neural crest-derived cell populations expressed YFP in the transgenic mice; however, no 
YFP was detected in the developing liver during the period desmin, a known marker for 
HSCs, was shown to be concomitantly expressed [50].   
 A more recent study has suggested HSCs may be derived from mesenchymal cells 
derived from mesoderm.  Cell lineage mapping was again conducted utilizing double 
transgenic mice; one transgene being MesP1 (mesoderm posterior 1), a transcriptio  
factor expressed in mesoderm, driven Cre and the second being lacZ floxed by a stop 
cassette [51].  The study indentified three populations of mesoderm-derived mesnchyme 
in the liver, with a sub-population of activated leukocyte cell adhesion molecule 
(ALCAM) positive cells being the precursors to HSCs in the developing liver [52].  The 
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mesodermal-derived hypothesis of HSC origin is further strengthened by theobservation 
that Foxf1 transcription factor is expressed in the developing and regenerating liver [53].   
Evidence suggesting HSCs may be derived from endoderm exists in the form of 
findings that stellate cells and hepatoblasts both exhibit transient expression of 
cytokeratins.  Specifically, a population of cluster of differentiation (CD) 34+/cytokeratin 
7/8+ cells were found in humans expressing markers for HSCs , including desmin and 
smooth muscle α-actin (αSMA) and possessed a morphology similar to stellate cells [54].   
HSCs represent 15% of the total number of resident liver cells and exist in two 
distinct phenotypes, with one being described as quiescent found in the normal liver [55].  
Quiescent HSCs possess many retinyl ester-containing lipid droplets in the cytoplasm 
which fluoresce under ultraviolet light, a key distinguishing characteristic [18].  
Additionally, quiescent HSCs have finely-branched cytoplasmic processes that wrap 
around the hepatic sinusoid [56].  HSCs in normal liver are distributed homogenously 
throughout the liver lobule, the functional unit of the liver.  However, there appears to be 
phenotypic variation among intralobular HSCs as those located near zone 3 store les 
retinyl esters as zone 1 HSCs [57].  Upon fibrogenic stimuli, HSCs transdifferentiate to 
an activated, myofibroblast-like phenotype.  Activated HSCs lose their cytoplasmic lipid 
droplets, undergo proliferation, possess the ability to migrate, express stress fibers, and 
secrete an abundance of fibrillar ECM components, specifically type I collagen [6].  
Additionally, the homogenous distribution of HSCs is lost, either through local 
proliferation and/or migration of activated HSCs in response to chemoattractive gents.   
 The specific mechanisms underlying the activation of HSCs remain unclear; 
however, a variety of factors that contribute to the activation of HSCs have been 
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identified.  Factors released from damaged liver cells, such as lipid peroxides, drug 
metabolites, such as acetaldehyde from the metabolism of ethanol, and reactive oxygen 
species (ROS) can activate the resident macrophage of the liver, the Kupffer cell.  
Activation of Kupffer cells can result in the release of cytokines that play a significant 
role in the activation process of HSCs.  Kupffer cells may also be activated by distal 
events, such as the increased permeability of the gut to the endotoxin lipopolysaccharide 
(LPS) following ethanol consumption.  LPS is a potent stimulator of Kupffer cells and 
may play a major role in ethanol-induced liver fibrosis [58]. Activated HSCs also express 
toll-like receptor 4 and stimulation with LPS increases inflammatory cytokine production 
through the transcription factor nuclear factor-kappaB (NF-κB) [59]. 
 Activation of HSCs can be categorized into two stages: the initiation phase and 
the perpetuation phase (Fig. 4).  In the initiation phase, quiescent HSCs undergo marked 
changes in gene expression and phenotype that renders it responsive to cytokines and 
other stimuli.  Factors leading to initiation of HSCs include infiltrating inflammatory 
cells (particularly neutrophils), injury to the hepatic parenchyma and neighboring 
sinusoidal endothelial cells (SEC), proliferation and paracrine stimulation from Kupffer 
cells, and changes in the surrounding ECM [60].  During the perpetuation stage, the 
activated phenotype of HSCs is maintained and even amplified by the increased 
expression of growth factors, as well as the enhanced response of HSCs to these factor .  
Whereas the events that mediate the initiation of activation are largely paracrine, the 
perpetuation of activation is comprised of both paracrine and autocrine stimuli.  
 In normal liver, quiescent HSCs store retinyl esters, play a role in hemodynamics 
by modulating sinusoidal diameter, and maintain the normal basement membrane.  These 
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HSCs secrete predominantly small amounts of type IV collagen and negligible amounts 
of fibrillar collagens such as types I and III.  The basement provides the proper
orientation of cells of the hepatic sinusoid as well as signals that maintain the 
differentiated state of surrounding cells.  This facilitates the proper delivery of oxygen 
and nutrients across the fenestrated SECs, perisinusoidal space of Disse, and 
subsequently to the parenchymal cells of the liver.  In response to chronic liver njury, 
activated HSCs are the principal cell type responsible for the substantial increase in the 
synthesis and secretion of type I collagen.  In activated HSCs there is a 60- to 70-fold 
increase in steady-state mRNA levels of α1(I) procollagen compared to quiescent HSCs 
[61].  The dramatic increase in α1(I) procollagen levels is thought to be largely due to an 
increase in mRNA half-life.  Although the transcription rate of α1(I) procollagen mRNA 
is two-fold higher in activated HSCs, the mRNA half-life is increased from 1.5 h in 
quiescent HSCs to > 24 h in activated cells.  The increase in mRNA half-life is though  t  
be caused by increased binding of proteins in the 3’ untranslated region of the α1(I) 
procollagen mRNA [61].   
 The most potent pro-fibrotic cytokine identified is TGF-β.  TGF-β stimulates the 
production and deposition of fibrillar ECM components such as type I and III collagen 
[62].  HSCs are a major source of TGF-β production in the liver, but Kupffer cells, 
hepatocytes, and platelets can also secrete this cytokine.  Furthermore, TGF-β 
sequestered in the ECM can be liberated following injury.  Thus in activated HSCs TGF-
β can stimulate in both autocrine and paracrine manners.  TGF-β signals through the 
constitutively active type II TGF-β receptor which in turn recruits and phosphorylates the 
type I receptor. This recruits Smad2 and Smad3 proteins which are both phosphorylated.  
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Smad2 and Smad3 then form a heterotrimeric complex with Smad4, resulting in the 
translocation of the complex to the nucleus where it interacts with specific DNA 
sequences to regulate transcription [63].  TGF-β has been reported as a potent inducer of 
both α1(I) and α2(I) collagen genes although a TGF-β response element has only been 
clearly identified in the promoter of the α2(I) collagen gene [64, 65].  
 Activated HSCs potentiate fibrosis not just through an increase in the rate of ECM 
component production, but also by increasing the pool of fibrogenic cells through 
proliferation.  Although HSCs can respond to a variety of mitogens, platelet-derived 
growth factor (PDGF) is considered the most proliferative stimulus.  Expression of PDGF 
and its receptor (PDGF-R) are up-regulated during activation of HSCs [66].  PDGF 
stimulation is associated with chemotaxis, loss of retinoids, and growth.  Expression of 
PDGF and its receptor are further modulated by other cells such as SECs and Kupffer
cells.  PDGF is a heterodimeric protein composed of either of its two polypeptide A and 
B chains.  HSCs have been shown to be most responsive to PDGF-BB, which is 
upregulated by TGF-β via increasing PDGF-BB mRNA levels [67].  Thus common 
mechanisms exist that upregulate both the proliferative and ECM-depositing capacities of 
HSCs upon their activation.   
 Another clinical manifestation of hepatic fibrosis is the hypercontractile nature of 
activated HSCs.  HSCs can contract and relax to regulate sinusoidal diameter dep ndant 
on a balance of vasodilators such as nitric oxide (NO) and vasconstrictors such as ET-1.  
Upon activation, HSCs initially upregulate production of both ET-1 and NO.  However, 
as disease progresses, the balance is shifted towards ET-1 [68].  Coupled with an increase 
in stress fibers in the cytoplasm, such as αSMA, activation of HSCs renders them 
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hypercontractile.  Hypercontractile HSCs inappropriately constrict the sinusoid diameter, 
further depleting the parenchyma of oxygen and nutrients and giving rise to portal 
hypertension.  This causes systemic consequences as the extra blood must be shunted 
away from the liver and often gives rise to esophageal varicies.   
 Resolution of underlying liver disease has been experimentally shown to result in 
spontaneous recovery with a reduction in the number of activated HSCs [7-12].  The 
decrease in HSCs may be attributed to one of two mechanisms: reversion of phenotype 
back to the quiescent state and apoptosis of activated HSCs.  Reversion of phenotype has 
been experimentally shown i vitro; however, it remains unclear whether this 
phenomenon can occur in vivo [69].  Activated HSCs express the cell surface death 
receptor Fas, and apoptosis can be induced with Fas ligands, such as Fas-activating 
antibodies [70].  TNF-α-mediated apoptosis, however, is inhibited by NF-κB activity, 
thus apoptosis of activated HSCs may require the downregulation of key survival signals. 
Type I collagen 
 Collagens are the main connective tissue protein in animals and are the most 
abundant protein found in mammals  [71].   Secreted into the ECM along with 
glycoproteins, proteoglycans, and elastins, collagens help maintain the integrity of many 
tissues by interacting with cell surfaces, other ECM components, and growth and 
differentiation factors  [72].  Collagens are synthesized as a triple helix from three 
polypeptide α chains composed of continuous Glycine- (Gly) X-Y peptide repeats  [73].  
Glycine is essential in the first position as its side chain is the only one small enough to 
fit within the center of the coiled-coil triple helix  [74].  Proline is frequently found in the 
X position and Hydroxyproline typically occupies the Y position  [75].  These two amino 
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acids limit rotation of the triple helical structure and their placement on the surface of the 
triple helix facilitates self-assembly and polymerization of collagen molecules through 
charge-charge and hydrophobic interactions [73]. 
 Type I collagen is a fibrillar collagen and is the most abundant protein in 
mammals, comprising much of the ECM scaffold in the tendons, skin, lungs and many 
other tissues such as bone where it provides the majority of its tensile strength [76].  Type 
I collagen is an important component in the wound-healing process and is found in large 
quantities in scar tissue associated with a variety of pathological conditions [77, 78].  In 
the liver, chronic damage stimulates activation of HSCs resulting in a phenotype change 
towards excessive production and secretion of ECM products, particularly type I collagen 
[18].   
 Synthesis of type I collagen is initiated by the expression of the col1a1 and col1a2 
genes [79].  Levels of these gene products can be regulated at both the transcriptional and 
post-transcriptional level [80].  Despite being located on different chromosomes, 
expression of these two genes are coordinately regulated in a tissue-specific manner 
giving rise to α1(I) and α2(I) procollagen mRNA products in a 2:1 ratio respectively [81, 
82].   Regulation of col1a1 and col1a2 gene transcription is regulated by the promoter 
and first intron [83-85].  The col1a1 and col1a2 genes can also be regulated through 
chemical modifications such as methylation [86].  Several CpG islands have been 
identified upstream of the promoter, and methylation of these sites causes a reduction in 
collagen gene transcription [87]. 
 A variety of cytokines and protein factors can modulate collagen expression.  
Several inflammatory cytokines such as TGF-β, interleukin-6 (IL-6), tumor necrosis 
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factor-alpha (TNF-α), and interleukin-1β have been shown to upregulate type I collagen 
production [88-91].  Nuclear factor-1 has been shown to be the required transcription 
factor for TGF-β-mediated upregulation of col1a2 transcription [92].  The basic 
transcription element binding protein (BTEB) and Sp1 [93] are zinc-finger family 
transcription factors that also enhance type I collagen production.  BTEB specifically is 
linked to c-jun N-terminal kinase- (JNK) dependent increases in type I collagen synthesis 
following UV irradiation [94].  Other cytokines have been implicated in the inhibition of 
type I collagen transcription, such as interleukin-10 (IL-10) [95], interferon gamma (IFN-
γ) [96], and fibroblast growth factor [97].  Modulation of collagen synthesis can also be 
regulated post-transcriptionally as demonstrated by increased mRNA stability [61].   
Translation of these mRNAs results in procollagen polypeptides of approximately 
1000 amino acids.  The polypeptide is flanked by globular C- and N-terminal propeptide 
domains and contains approximately 338 repeats of the Gly-X-Y motif [98].  Most 
proteins begin folding at the N-terminal prior to completion of translation and 
translocation.  For type I collagen, however, folding is initiated at the C-terminal 
following cotranslational translocation into the endoplasmic reticulum (ER) [99].  Several 
proteins play an important role in facilitating the proper folding and trafficking of α 
chains into triple helix procollagen molecules.  The 78-kDa glucose-regulated protein 
(Grp78) recognizes hydrophobic residues on polypeptide chains to help maintain 
solubility and may also bind the C-propeptide [100].   Protein disulfide isomerase (PDI) 
also plays a role in triple helix formation by catalyzing disulfide bonds between C-
propeptide domains of the three α chains [101, 102].  PDI also acts as a subunit for prolyl 
4-hydroxylase (P4H) by keeping the catalytic α-subunits in a soluble state [103].  Further 
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stabilization of the triple helix is accomplished through hydroxylation of select proline 
residues (typically in the Y position) by the P4H enzyme which in turn facilitates 
hydrogen bonding and the formation of water bridges within and between collagen chains
[104, 105].  The 47-kDa heat shock protein (Hsp47) is a collagen-specific chaperone 
which also plays an important role in collagen trafficking [106].  Although the exact role 
of Hsp47 has not been clearly defined, studies utilizing Hsp47-/- mice showed they are 
embryonically lethal at day 11.5 [107].  After procollagens traverse the Golgi apparatus 
and are secreted into the extracellular space, the C- and N-prodomains are cleaved by C- 
and N-peptidases respectively  [108].  This process drops the concentration required for 
fibril formation and results in the self-assembly of collagens into fibrils [109] (Fig. 5).  
Nuclear Factor-kappaB 
HSCs upon activation also undergo gene expression changes that further 
exacerbate injury through the recruitment of inflammatory molecules.  NF-κB is a redox-
sensitive transcription factor which has been implicated in stimulating an increase in 
inflammation in the injured liver [110].  NF-κB is composed of members of the Rel 
family (p65, p50, p52, c-Rel, and RelB).  Each member contains a consensus DNA 
binding domain, a dimerization domain that allows both the formation of homo or 
heterodimers, and a nuclear localization signal (NLS) [111].  Although all members 
contain a DNA binding domain, only the p65, c-Rel, and RelB are considered 
transcriptional activators wherase p50 and p52 are generally associated with 
transcriptional repression [112, 113].  In the cytoplasm the repressor IκBα is bound to the 
NLS of NF-κB, sequestering the complex in the cytoplasm.  In response to the 
appropriate stimulus, IκBα is phosphorylated by the IκB kinase (IKK) complex and is 
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polyubiquinated and subsequently degraded by the 28S proteosome [114].  Degradation 
of IκBα liberates NF-κB by unmasking the NLS, allowing translocation to the nucleus to 
bind specific sequences and alter gene expression [115].   
There are two major pathways that lead to the activation of NF-κB.  In the 
canonical activation of NF-κB a variety of upstream stimuli such as IL-1, TNF-α, and 
Toll-like receptor signaling leading to the phosphorylation and activation of the IKK β 
subunit of the IKK complex [110].  In non-canonical activation of NF-κB, a limited 
number of stimuli such as CD40 activates the IKKα subunit, typically leading to 
activation of p52/RelB heterodimers as opposed to p65/p50 heterodimers with subsequent 
activation of a different group of gene targets [110]. 
 In quiescent HSCs the p50/50 homodimer dominates and is mainly sequestered in 
the cytoplasm.  Upon activation, there is an increase in the p65/50 complex [116].  
Activators of p65/50 in HSCs include acetaldehyde and TNFα leading to the transcription 
of inflammatory gene products such as intracellular adhesion molecule-1, macroph ge 
inflammatory protein-2, and IL-6 [117, 118].  NF-κB activation, however, does not 
appear to affect the activation of HSCs [119].  Paradoxically, p65/50 appears to inhibit 
the col1a1 and col1a2 genes in activated HSCs, suggesting NF-κB has a complex role in 
activated HSCs [120, 121]. 
Matrix Metalloproteinases 
 The ECM is a complex network of protein and macromolecules that provides a 
variety of functions to the surrounding cells and tissues.  Constituents of the ECM are 
typically divided into three categories:  collagens, glycoproteins, and proteoglycans.  The 
most widely appreciated role of the ECM is the ability of collagens to provide a basement 
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membrane and support to a variety of tissue types.  The ECM also is involved in 
regulation of biological functions through the expression of integrins on cells interacting 
with the ECM.  Type I collagen can stimulate cell division by interacting with integrin β1 
to induce focal adhesion kinase phosphorylation and activation of phosphoinositide-3 
kinase. 
 The composition of the ECM must be tightly regulated to ensure normal 
biological function of the surrounding tissues.  A net accumulation of ECM components 
(either through excessive production or a decrease in degradation) results in fibrotic 
conditions, regardless of the site.  However the ECM is a dynamic environment 
undergoing constant turnover.  Thus, a means of tightly regulating the accumulation and 
destruction of ECM components must exist. 
 Regulation of the ECM is accomplished in part by a diverse family of calcium- 
and zinc-dependant endopeptidases called MMPs.   There are 25 identified unique 
members of the MMPs, of which 24 are found in mammals, and they are capable of 
degrading a variety of matrix components.  MMPs can be divided into five categories: 
interstitial collagenases, gelatinases, stromelysins, membrane-type collagenases, and a 
metalloelastase (MMP-12) although there is some overlap in function between thes 
groups.  MMP-1, MMP-8, MMP-13 are the interstitial collagenases; however, MMP-2 (a 
gelatinase) and MT1-MMP (a membrane-type collagenase) can work together to cleave 
interstitial collagens [122, 123].  Although the main function of the MMPs has long been 
considered to be the degradation of ECM components from tissues, increasing evidence 
suggests cleavage of ECM and cell-surface molecules by MMPs can alter cell-matrix and 
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cell-cell interactions, affecting biological function and releasing growth factors 
sequestered within the ECM [124].   
 Structurally, typical MMPs consist of a propeptide of approximately 80 amino 
acids containing a ‘cysteine switch’ with the PRCGXPD consensus sequence, a catalytic 
domain of approximately 170 amino acids, a linker peptide commonly referred to as the 
‘hinge region’, and a hemopexin domain of approximately 200 amino acids which is 
considered important in substrate recognition [125].  The propeptide maintains the 
zymogen in the inactivated state by coordinating a Cys residue with a Zn2+ ion bound to 
the HEXXHXXGXXH motif within the catalytic domain, resulting in the exclusion of a 
water molecule necessary for catalysis [125].   
 MMPs have evolved multiple levels of regulation due to their important role 
regulating the ECM.  In the normal steady-state tissue, the activity of most MMPs is low 
with transcription upregulated by inflammatory cytokines, growth factors, hormones, and 
cell-cell and cell-matrix interactions [126].  MMPs are translated as pre-proenzymes with 
a signal peptide, which is cleaved during translation, targeting them for secretion (or 
insertion into the membrane as with the MT-MMPs).  Following secretion, the zymogen 
can be activated by cleavage of the propeptide domain.  This often occurs in a ‘stepwise 
process’ requiring the presence of two or more proteinases [127].  Transient MMP 
activation can also occur in the presences of oxidants in inflammatory settings through 
reactions with the cysteine switch of the propeptide [128, 129]. 
 MMPs are also regulated through protein-protein interactions via two types of 
inhibitors: α2-macroglobulin and TIMPs.  α2-macroglobulin inhibits MMPs by entrapping 
the proteases within a complex with α2-macroglobulin and subsequent clearance through 
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the low density lipoprotein receptor-related protein-1 [130].  Four TIMPs have been 
identified (TIMP-1, TIMP-2, TIMP-3, and TIMP-4) each consisting of 184-194 amino 
acids.  TIMPs inhibit MMPs by directly binding to the catalytic domain of MMPs in a 1:1 
stoichiometric ratio.  TIMPs have been shown to inhibit the activity of each MMP, 
though with varying efficiency [131].  In particular TIMP-1 is a poor inhibitor of MT1-
MMP [132]. 
 The expression profiles of MMPs and their inhibitors play an important role in the 
progression and resolution of hepatic fibrosis as there is a ten-fold increase in the 
deposition of ECM components, particularly interstitial collagens, during fibrosis [133].  
In particular, MMP-1 (MMP-13 in rodents), MMP-2, MMP-9, MT1-MMP, TIMP-1, and 
TIMP-2 show significant changes in their expression and activity profiles during the 
initiation, progression, and resolution of hepatic fibrosis (Fig. 6).   
 In the liver the main interstitial collagenase is MMP-1 in humans and MMP-13 in 
rodents.  MMP-3 (stromelysin-1) is another interstitial collagenase expressed in liver, 
however, it exhibits weak proteolytic activity towards ECM components [134].  MMP-13 
expression in the liver is expressed by HSCs, fibroblasts , Kupffer cells, and inusoidal 
endothelial cells [26].  Expression of MMP-13 mRNA can be stimulated by a variety of 
inflammatory cytokines and growth factors including IL-1α, IL-1β, TNF-α, and EGF 
[135-138].  TGF-β does not influence the expression of MMP-13; however, it has been 
shown to abrogate the expression of MMP-1 [136, 139]. 
 In animal models of fibrosis, MMP-13 levels rise shortly after initial injury and 
decline to baseline levels as fibrosis develops [140].  This initial peak of expression may 
actually be deleterious, as MMP-13 may destroy surrounding tissue permitting the 
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deposition of newly synthesized ECM components and the liberation of inflammatory 
cytokines sequestered in the ECM.  Disruption of MMP-13 expression during 
fibrogenesis attenuates injury, supporting a role in initiating injury [141].  Following 
withdrawal of the noxious stimulus, hepatic fibrosis undergoes spontaneous resolution.  
Associated with the resolution is a rise in the expression of MMP-13.  The source of 
MMP-13 during resolution of hepatic fibrosis may be scar-associated macrophages, as 
HSCs undergoing apoptosis would no longer be an adequate source of MMP-13 secretion 
[142].  The role of MMP-13 in hepatic fibrosis appears to be dual:  in the initiation of 
injury, MMP-13 can disrupt the normal ECM permitting the deposition of newly 
synthesized ECM products by HSCs.  Disruption of the ECM can also release 
sequestered pro-fibrotic cytokines such as TGF-β, further perpetuating injury.  In the 
resolution of injury, MMP-13 can cleave interstitial collagens such as type I collagen 
allowing restoration of the normal liver architecture.  Increasing MMP-13 activity is an 
attractive therapeutic, but attention should be paid to the stage of injury. 
 The gelatinase MMP-2 and the membrane-type collagenase MT1-MMP appear to 
be involved together in hepatic fibrosis as both collagenases are expressed in HSCs
following liver injury [135].  Studies have suggested that the transcription of MMP-2 and 
MT1-MMP in HSCs may be co-regulated [143].  MMP-2 appears to be activated by 
MT1-MMP at the cell surface when a ternary complex is formed between proMMP-2, 
MT1-MMP, and TIMP-2 [144].   
 In normal liver, levels of both MMP-2 and MT1-MMP mRNA are low [145].  
However, following injury in both CC14 and BDL models of experimental fibrosis, there 
is sustained increase in the expression of both proteins during initiation, fibrogenesis, a d 
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resolution [146, 147].  Despite sustained elevation during hepatic injury, MMP-2 appears 
to have a diverse role.  MMP-2 is a stimulator of proliferation and migration of activated 
HSCs and is upregulated by ROS and TGF-β in cultured human HSCs [148].  In the 
resolution of hepatic fibrosis there is a decline of TIMP-1 levels despite sus ained levels 
of MMP-2 and MT1-MMP which may be at least partially responsible for fibrolysis in 
resolution of hepatic fibrosis [149].   
 MMP-9 is another gelatinase expressed in liver during hepatic fibrosis.  It is 
expressed under inflammatory conditions by several cell types in the liver.  MMP-9 is 
produced in vitro by TNF-α- or IL-1β-stimulated hepatocytes, IL-1α-stimulated HSCs, 
and activated Kupffer cells [135, 136, 150].  MMP-9 is activated by MMP-3 and can 
cleave latent TGF-β into the active form, possibly influencing hepatic fibrosis [151].  In 
experimental models of fibrosis, MMP-9 is elevated and likely sources included HSCs 
and inflammatory cells such as neutrophils [136, 152].   
 Important modulators of hepatic fibrosis may be TIMP-1 and TIMP-2.  TIMP-1 
expression is mediated by a number of inflammatory cytokines such as IL-1β, I -6, TNF-
α, and TGF- β [139, 153, 154].  In the fibrotic liver, TIMP-1 appears to be principally 
produced by HSCs in both CCl4 and BDL models of injury [155, 156].  To illustrate the 
importance of TIMP-1 in hepatic fibrogenesis, studies utilizing TIMP-1 overexpressing 
mice showed severe injury in a CCl4 model of liver fibrosis as compared to control mice.  
However, TIMP-1 alone does not induce fibrosis [157, 158].  Additionally TIMP-1 
antisense therapy and neutralizing antibodies were shown to lessen hepatic fibrosis [159, 
160].  Besides the well-established direct role of TIMPs as inhibitors of MMPs, TIMP-1 
is capable of indirect inhibition of HSC apoptosis [157, 161].  Furthermore, reduction of 
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TIMP-1 levels is associated with increased hepatocyte proliferation via degr dation of 
fibrotic ECM to permit hepatocyte expansion and liberation of ECM-bound hepatocyte 
growth factor [162]. 
 TIMP-2 expression in liver cells was detected in activated HSCs, Kupffer cells, 
and myofibroblasts [135].  In models of liver fibrosis, TIMP-2 expression was elevat d in 
a BDL model but not a CCl4 model of disease [147, 149].  TIMP-2 may be most relevant 
in the earlier stages of hepatic fibrosis, as it is responsible for activation of MMP-2 along 
with the presence of MT1-MMP. 
 MMPs and their inhibitors clearly play an important role in the development, 
progression, and resolution of hepatic fibrosis.  However, the context of MMP and TIMP 
expression must be considered when developing therapeutic strategies to target their 
activity.  In early stages of hepatic fibrosis, MMPs appear to play a deleterious role, 
whereas in the resolution of fibrosis, MMP activity is critical to reduce the scar and 
achieve restoration of the normal liver architecture. 
Endoplasmic Reticulum Stress 
 In cells there is a constant synthesis and degradation, or “turnover”, of proteins.  
When eukaryotic cells are subjected to stress, two mechanisms are employed to maintain 
protein stability: the heat-shock response which occurs in the cytosol and the unfolded 
protein response (UPR) which occurs in the endoplasmic reticulum (ER) [163, 164].  
Unlike the heat-shock response, the UPR is a normal physiological process that allows 
cells to expand their production of proteins for secretion through the upregulation of 
molecular chaperones responsible for transporting and facilitating proper prot in 
structure. 
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 Nascent polypeptides enter the ER in the unfolded state where they then 
encounter specific chaperones which fold and modify the proteins for subsequent 
secretion [165].  In the ER proteins undergo quality control which differentiate betw en 
properly folded and misfolded or improperly assembled proteins.  Misfolded proteins are 
eliminated from the ER through retro-translocation through the Sec61 complex [166] into 
the cytoplasm and subsequent polyubiquitination and ultimately degradation by the 26S 
proteasome in a process called ER-associated degradation (ERAD) [165, 167].  
Perturbations that signal the ERAD process include an increase in secretory pro ein 
synthesis, accumulation of mutant or misfolded proteins, deprivation of glucose, Ca++ 
depletion within the ER, and a shift in redox status within the cell [168].  
 The UPR is typically mediated by three intracellular sensors:  type-I ER 
transmembrane protein kinase (IRE1), activating transcription factor 6 (ATF6) and the 
PKR-like ER kinase (PERK) [169-172].  In each instance the ER luminal domains of 
these proteins bind to the Grp78 under normal physiological conditions.  Upon conditions 
resulting in an increase in the unfolded protein burden within the ER, Grp78 dissociates 
with these ER-resident sensors and binds to the unfolded proteins.  This in turns 
generates signal transduction events among the sensor proteins:  IRE1 dimerizes and is 
autophosphorylated and ATF6 is cleaved to generated nATF6 with both translocating to 
the nucleus to stimulate the production of new chaperone proteins.  PERK 
autophosphorylates and in turn phosphorylates eIF-2a which attenuates transcription 
[168].  Thus by increasing the production of chaperone proteins and decreasing the 
amount of nascent polypeptides being delivered to the ER, while retro-translocating 
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misfolded proteins for proteasomal destruction, the cell can clear the accumulation of 
misfolded proteins. 
 While the UPR is a normal response, prolonged UPR and ERAD can be 
deleterious to the cell.  Retrotranslocation of unfolded proteins for degradation is an 
energy-dependent process, which is a contributing factor in apoptosis [173, 174].  
Prolonged ER stress is also linked to a release of ER stores of Ca++ into the cytosol, 
potentially damaging the mitochondria and generating oxidative stress, which can in turn 
lead to inflammation through activation of NF-κB [175, 176].  Chronic ethanol 
consumption can also lead to prolonged ER stress through hyperhomocysteinemia [177, 
178].  
Ethanol and Oxidative Stress 
 Worldwide, the principal cause of hepatic fibrosis is viral hepatitis.  However, 
excess consumption of ethanol is the leading cause of liver fibrosis in the United Stat s 
and Europe.  Strongly associated with the onset of fibrosis is the development of 
oxidative stress.  Oxidative stress following chronic ethanol abuse is consequence not 
only of its metabolism, but of the serious alterations in critical dietary nutriets involved 
in maintaining overall antioxidant status.  Chronic ethanol consumption through its intake 
and metabolism likely causes damage not only through pro-oxidant production but also 
via a decrease in anti-oxidant defense.   
 Three metabolic pathways for ethanol have been identified in the liver: 
cytoplasmic alcohol dehydrogenase (ADH), the inducible microsomal ethanol-oxidizing 
system (MEOS) found in endoplasmic reticulum, and catalase located within 
peroxisomes [179-181].  Each pathway generates a specific toxic metabolit , 
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acetaldehyde being a common metabolite.  The hepatocyte is the main site for ethanol 
metabolism and utilizes all three pathways.  It is through the metabolism of ethanol hat 
the majority of reactive oxygen species (ROS) and reactive nitrogen specie  are 
generated. 
 ADH is a constitutively-expressed zinc metalloenzyme with eight different types 
of subunits (α, β1, β2, β3, γ1, γ2, π, and χ) that arise from 5 gene loci [181].  A recently 
identified new subunit (σ) has also been discovered from human stomach.  ADH converts 
ethanol to acetaldehyde with the loss of H+, which in turn reduces NAD to NADH.  With 
chronic ethanol consumption, the large burden of reducing equivalents prevents the 
hepatocyte from maintaining redox homeostasis [182].  Perturbations in hepatocyte 
homeostasis result in a variety of metabolic disorders, such as hypoglycemia and 
hyperlacticacidemia [183].  The increased accumulation of NADH also promotes fat y 
acid synthesis and opposes β-oxidation of lipids, resulting in fat accumulation; a finding 
described as steatohepatitis [183].  Disruption of the redox state of cells can also 
stimulate redox-sensitive transcription factors such as NF-κB leading to an increase in 
inflammation in the liver. 
 The key enzyme of the MEOS is the ethanol-inducible cytochrome P450 2E1 
(CYP2E1).  CYP2E1 catalyzes the conversion of ethanol to acetaldehyde utilizing NADP 
as a proton acceptor.  This reaction has been shown to be loosely coupled to cytochrome 
reductase, providing a source of electrons to oxygen to form superoxide anion or cause 
lipid peroxidation [184]. The induction of CYP2E1 is transcriptionally regulated and its 
expression stimulated by ethanol consumption; samples from liver biopsies of recently-
drinking individuals showed a 4- to 10-fold increase in CYP2E1 levels [185].  The 
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induction of CYP2E1 results in a metabolic tolerance to ethanol that exists in addition to 
CNS tolerance [186].  This is significant as rapid metabolism of xenobiotics (includi g 
ethanol, acetaminophen, and social drugs of abuse commonly linked to ethanol 
consumption) can overwhelm the main intracellular antioxidant, glutathione.  Animals 
fed ethanol chronically show increased glutathione (GSH) turnover, and an increased in 
oxidized glutathione (GSSG) [187].   
 Ethanol may also lead to oxidative stress in nonparenchymal cells in addition to 
hepatocytes.  Kupffer cells have been shown to produce ROS via NADPH oxidase 
following chronic infusion of ethanol in mice via a gastric feeding tube as evidence by 
electron spin resonance.  However p47phox knockout mice which lack a critical subunit of 
the NADPH oxidase showed no liver pathology [188].  The metabolism of ethanol in 
HSCs is controversial, however.  HSCs have been shown to express ADH but conflicting 
data exists in the literature regarding CYP2E1 [189, 190].  However, given the ratio of 
HSCs to parenchymal cells in the liver, it is expected the majority of ethanol metabolism 
via ADH would occur in hepatocytes [191].   
 HSCs, given their proximity to both hepatocytes and Kupffer cells, are subject to 
paracrine and systemic effects of ethanol metabolism.  Although the primary product of 
ethanol metabolism, acetaldehyde, is metabolized to acetate via aldehyde derog nase, 
the activity of this enzyme is sufficiently slow to allow accumulation of acetald hyde 
systemically; many of the physical effects of hangovers have been ascribed to 
acetaldehyde.  Acetaldehyde is known to potentiate collagen transcription though te 
precise action remains unclear [192].  However, it is known that acetaldehyde can form 
adducts with proteins via Schiff bases, most commonly with the α-amino group of lysines 
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[193, 194].  These acetaldehyde-protein adducts can be detected in the livers of ethanol-
fed rats and the majority of alcoholic individuals have antibodies against these adducts in 
their serum.  This may compound disease progression by promoting auto-immunity in the 
liver [195]. 
 Acetaldehyde-dependant increases in collagen transcription appear to be 
dependent on de novo protein synthesis.  Treatment of HSCs with acetaldehyde 
stimulates the binding of the transcription factor BTEB to a region of the α1(I) collagen 
promoter originally described as the UV response element [94].  The production of BTEB 
following acetaldehyde stimulation appeared to be mediated by JNK [94]. 
 Ethanol consumption also leads to nutritional deficiencies that can deplete 
antioxidants in the body.  Ethanol is a very energetic compound, and chronic alcoholics 
can receive as much as 50% of their calories from ethanol consumption [196].  Thus the 
reduction in the diet of protein, nutrients, and vitamins can perturb metabolic pathways 
and deplete key intermediates in antioxidant pathways.  Ethanol consumption has been 
shown to deplete methionine and decrease absorption of folate from the gut [197].  Both 
compounds are important intermediates in the regeneration of the intracellular antioxid t 
glutathione.   
 Prolonged ethanol consumption can cause significant liver injury.  Through both 
the metabolism of ethanol and the actions of its metabolites, there is a tremendous 
generation of oxidative stress and alteration of the redox state, particularly in the liver.  
Antioxidant stores are further depleted by ethanol consumption via the decrease of 
upstream intermediates such as folate and methionine.  Thus the identification of 
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therapies that can correct the altered nutritional and antioxidant state of the body remain 
attractive. 
S-adenosyl-L-methionine 
 S-adenosyl-L-methionine (SAMe) is a pleiotropic molecule found in all living 
organisms.  The importance of SAMe is due to its ability to participate in a diverse 
number of biological reactions, likely second only to ATP.  SAMe is the principal 
biological methyl donor, the precursor of aminopropyl groups used in polyamine 
biosynthesis, and in the liver is also a precursor to glutathione by conversion to cysteine 
via the trans-sulfuration pathway (Fig. 7) [198].  Therefore, deficiency in SAMe can be 
expected to have major detrimental effects on cellular function, given the importance of 
methylation in processes such as gene expression and membrane fluidity.  Accumulating 
evidence has shown that SAMe administration can attenuate liver disease, and studies 
have shown SAMe as a treatment for depression [199].  
 Though SAMe is synthesized in the cytoplasm of all cells, the liver is the primary 
site of SAMe homeostasis [200].  Generation of SAMe is catalyzed by methionine 
adenosyltransferase (also called s-adenosylmethionine synthetase) by th  introduction of 
an adenosyl group from ATP to form a high-energy sulfonium ion, generating a molecule 
that readily loses its methyl group to a variety of substrates such as proteins, nucleic 
acids, phospholipids, and amines [201].  Half of the dietary intake of methionine is used 
to synthesize SAMe, with approximately 95% of the 6-8 g produced each day used in 
transmethylation reactions [202].  Less than 5% of SAMe metabolism is attributed to 
polyamine synthesis, although this amount can increase during liver regeneration [202].  
Demethylation of SAMe generates S-adenosylhomocysteine (SAH).  SAH is a potent 
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inhibitor of transmethylation reactions, necessitating its rapid removal.  In the liver, SAH 
is cleared by its conversion to cysteine, demonstrating a role for SAMe as a precursor to 
glutathione [203]. 
 With oxidative stress a prominent feature of ethanol-induced liver fibrosis, a role 
for antioxidants has long been pursued as a treatment for liver disease.  However, 
exogenous administration of antioxidants such as vitamin E, carotenoids, and glutathione 
have failed to show any significant benefit in human patients with liver disease [36, 37, 
204].  In contrast, a variety of animal studies have shown a benefit when attempting to 
modulate liver disease with antioxidant therapies.  In particular, SAMe has shown 
beneficial effects in several fibrotic animal models [205-208].  Additionally,  clinical 
trial of patients with alcoholic liver cirrhosis, SAMe treatment resulted in delayed 
transplantation and increased survival [209].   
 While the beneficial effects of SAMe in experimental models of injury have been
well accepted, little is known about its mechanism of action.  In rodent models of 
fibrosis, SAMe decreased several markers of liver injury such as liver transaminases and 
bilirubin levels.  Furthermore, SAMe was shown to decrease hepatic collagen contt by 
hydroxyproline assay [210].  However, no studies have been performed to determine the 
molecular mechanisms of SAMe in activated HSCs.  Given its property as the principal 
biological methyl donor, SAMe may be acting to decrease type I collagen by methylating 
DNA.  The α1(I) and α2(I) collagen promoters are both rich in CpG islands, the main sites 
of DNA methylation.  With methylation often associated with gene silencing, SAMe may 
be methylating the promoters to repress their transcriptional activation. 
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Another potential mechanism for SAMe-mediated decreases in hepatic collagen is 
its role as an antioxidant.  SAMe as mentioned is a precursor to the main intracellular 
antioxidant glutathione.  By restoring antioxidant levels in the liver and reestablishing 
proper redox balance, SAMe may decrease the activation of redox-sensitive transcriptio  
factors such as AP-1 and NF-κB.   
Hypothesis 
We hypothesize that SAMe can inhibit type I collagen production in culture-
activated hepatic stellate cells.  Furthermore, we hypothesize that SAMe functions to 
decreases oxidative stress mediated by the redox-sensitive transcription fac or NF-κB.  In 
order to address these hypotheses, we also developed an animal model of ethanol-induced 
hepatic fibrosis utilizing the Lieber-DeCarli liquid ethanol diet with concurrent injections 
of LPS in a “two-hit” model of liver fibrosis. 
 
 
 
 
 
 
 
Figure 1.  Pericentral and periportal zones of the liver.  Fibrosis begins in zone 1 when 
hepatitis or cholestasis causes liver injury, whereas zone 3 is initially damaged during 
ethanol-induced fibrosis and carbon tetrachloride exposure.  
vein. 
 
 
P- portal vein, 
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Figure 2.  Architecture of hepatic sinusoid and localization of hepatic stellate ce ls. The 
hepatocyte is the primary cell type of the liver and is separated from blood flow by 
sinusoidal endothelial cells by the space of Disse.  HSCs reside in the space of Disse and 
Kupffer cells are the resident macrophages found in the sinusoidal lumen. (Adapted from 
Bataller et al. 2005) 
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Figure 3. Cre-mediated DNA recombination allowing conditional expression of 
transgenes flanked by loxP.   
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Figure 4.  Activation of hepatic stellate cells.  Quiescent HSCs are vitamin A-storing cells 
that reside in the space of Disse.  Upon exposure to a noxious stimulus, HSCs undergo a 
phenotypic change to an activated, myofibroblast-like state characterized by loss of
vitamin A and expressin of stress fibers.  Activated HSCs migrate to the site of injury, 
proliferate, and secrete collagen and cytokines to facilitate wound healing.  (Adapted with 
permission from Rippe, RA) 
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Figure 5.  Processing of type I collagen.  Following translation, nascent procollagens 
enter the ER where they undergo extensive modification and folding into a triple helix by 
ER resident proteins.  Upon secretion into the extracellular space, N- and C-terminal 
prodomains are cleaved by peptidases, resulting in the mature type I collagen molecule.  
Type I collagens molecules sponatenously arrange and assemble into fibrillar 
supramolecules.
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Figure 6.  Expression profile of MMPs and their inhibitors.  Graphic representation of the 
expressin of MMPs and TIMPs during the initiation, progression, and resolution of 
hepatic fibrosis. (Adapted from Hemmann et al. 2007) 
 
 
 
 
 
  
 
 
 
Figure 7.  Synthesis and metabolic pathways for SAMe.  SAMe is a precursor for the 
intracellular antioxidant glutathione via the trans
2000) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-sulfuration pathway. (Adapted from Lu 
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CHAPTER 2: MATERIALS AND METHODS 
 
 
Isolation and culture of Hepatic Stellate Cells 
Primary hepatic stellate cells (HSCs) were isolated from maleSprague-Dawley 
retired breeder rats (>400g) [211, 212].  Rats where anesthetized with isofluorane.  The 
hepatic portal vein was canulated, and rats were exsanguinated by cutting the inferior 
vena cava.  The liver was first perfused with approximately 200 mL of Minimum 
Essential Medium (S-MEM, without calcium) (Invitrogen, Carlsbad, CA) supplemented 
with 1X Antibiotic-Antimycotic suspension (Sigma-Aldrich, St. Louis, MO).  The liver 
was then digested with Gey’s Balanced Salt Solution (GBSS) (137 mM NaCl, 2.7 mM 
NaHCO3, 5.0 mM KCl, 1.5 mM CaCl2·2H2O, 1.0 mM MgCl2·6H2O, 0.7 mM Na2HPO4, 
0.2 mM KH2PO4, 0.3 mM MgSO4·7H2O, 5.5 mM glucose, 25 mM HEPES) containing 
0.045% (w/v) pronase (Roche, Indianapolis, IN) and 0.05% (w/v) type IV collagenase 
(Sigma-Aldrich) supplemented with 1X Antibiotic-Antimycotic suspension.  Following 
digestion, the liver was mechanically agitated at 37ºC for 10 min in GBSS containing 1X 
Antibiotic-Antimycotic suspension and 20 µg/mL DNase1 (Sigma-Aldrich).  Hepatocytes 
were removed by centrifugation at 50 x g for 2 min in an Eppendorf (Hamburg, 
Germany) 5810 R centrifuge with an A-4-62 swing-bucket rotor and the nonparenchymal 
cell-containing supernants were transferred to fresh 50 mL conical tubes after each spin.  
Nonparenchymal cells were isolated by centrifugation at 700 x g for 7 min.  The 
nonparenchymal cell suspension was layered on an arabinogalactan (Sigma-Aldrich) 
41 
 
gradient using 1.035 and 1.045 g/mL densities.  The cells were centrifuged at 61,120 x g 
for 35 min at 20ºC in a SW40 Beckman swinging-bucket rotor (Beckman Instruments, 
Inc., Fullerton, CA).  Pure HSCs were recovered from the interface between the GBSS 
and 1.035 g/mL layers.  HSCs were cultured on plastic using Dulbecco’s Modified 
Eagle’s Medium (DMEM) (Gibco, Grand Island, NY) supplemented with 10% fetal calf 
serum (FCS) (Atlanta Biologicals, Lawrenceville, GA), 2 mM L-glutamine (Gibco), and 
1X Antibiotic-Antimycotic suspension (Sigma-Aldrich) in a 95% air-5% CO2-humidified 
atmosphere at 37ºC.  HSCs were spontaneously activated by culturing on plastic for 13-
15 days.  Media was changed every 48 h, with the exception of one media change 24 h 
after initial plating of HSCs.  All experimental procedures were approved by the 
Institutional Animal Care and Use Committee and performed in accordance with the 
National Institutes of Health criteria for care and use of laboratory animals. 
Treatment of HSCs 
S-adenosyl-L-methionine (SAMe) and acetaldehyde were purchased from Sigma-
Aldrich.  To inhibit p38 MAPK activity, cells were pretreated with 5 µM SB203580 
(CalBiochem, San Diego, CA) for 30 min prior to treatment with SAMe.  Where 
acetaldehyde was used, cells were pretreated with SAMe for 30 min prior to the addition 
of acetaldehyde.  Cells were serum-starved in 0.2% (v/v) (HSCs) or 0.5% (v/v) FCS (Rat-
1 fibroblasts and NIH 3T3 fibroblasts) for 24 h prior to the addition of SAMe.  Viability 
of cells was assessed by Trypan Blue exclusion. 
Isolation of RNA and cDNA generation 
 Total RNA was isolated from HSCs (6-well plate) or liver tissue (approximately 
50 mg) using 1 mL of TRIzol reagent (Gibco-BRL, Gaithersburg, MD).  Homogenates 
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were placed in 1.5 mL microcentrifuge tubes and incubated in TRIzol for 5 min at room 
temperature to permit the complete dissociation of nucleoprotein complexes.  Following 
incubation, 0.2 mL of chloroform was added to each tube and shaken vigorously.  Tubes 
were then centrifuged at 12,000 x g for 15 min at 4ºC.  Following centrifugation, the 
aqueous phase was transferred to fresh 1.5 mL microcentrifuge tubes, and RNA was 
precipitated by addition of 900 µL of isopropanol for 10 min at room temperature.   
Samples were then centrifuged for 10 min at 12,000 x g at 4ºC.  Supernants were then 
decanted, and RNA pellets washed in 1 mL of 75% ethanol and immediately centrifuged 
at 12,000 x g for 5 min at 4ºC.  Supernants were again decanted; samples were pulse-
centrifuged, and remaining ethanol aspirated using a 200 µL pipet tip.  Pellets were then 
suspended in 12 (RNA from HSCs) or 50 (liver tissue) µL of diethylpyrocarbonate 
(DEPC)-treated H2O.  RNA quantification was performed using a GeneSpec 
spectrophotometer (MiraiBio, South San Francisco, CA).  
Ribonuclease Protection Assay 
 
Radiolabeled riboprobes for the RNase protection assay were derived from the 
375-nucleotide PstI-AvaI fragment of rat α1(I) procollagen cDNA. The riboprobe for the 
rat GAPDH gene was generated from the plasmid pTRI-GAPDH-Rat (Ambion, Austin, 
TX), which was linearized with HindIII. Radiolabeled probes were mixed with 5 µg of 
total RNA, and the dried pellets were suspended in 30 µL of hybridization buffer 
(100 mM PIPES, pH 6.7, 400 mM NaCl, 2 mM EDTA, and 80% formamide). Samples 
were heated at 85°C for 10 min and then incubated at 45°C overnight. The hybridization 
reaction was then performed at 37°C for 1 h in RNase buffer (300 mM NaCl, 10 mM 
Tris·HCl, pH 7.6, 40 µg/mL RNase A, and 2 mg/mL RNase T1). Subsequently, 20% SDS 
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and proteinase K (10 µg/mL) were added, and the reaction mixture was incubated at 37°C 
for an additional 15 min. The reaction mixture was extracted with phenol and precipitated 
with the addition of yeast tRNA and 100% ethanol. The samples were suspended in 
formamide dye (95% formamide, 20 mM EDTA, 0.05% bromophenol blue, and 0.05% 
xylene cyanol FF) and loaded onto a standard 6% sequencing gel. After electrophoresis, 
bands were visualized by autoradiography and quantitated with a PhosphorImager 
(Molecular Dynamics, Sunnyvale, CA). 
Reverse Transcription of RNA 
 To eliminate contaminating genomic cDNA, 1 µL RQ1 RNAse-free DNase 
Reaction Buffer (Promega) and 1 µL RQ1 RNAse-free DNase (Promega) was added to 8 
µL of HSC total RNA or 2 µg of liver tissue total RNA (quantum sufficit o 8 µL with 
DEPC-treated H2O) and incubated at 37ºC for 30 min in 0.5 mL microcentrifuge tubes.   
Following incubation, 1 µL of RQ1 RNAse-free DNase Stop Solution and 1 µL of 
DEPC-treated H2O were added to each tube.  Following DNase treatment, total RNA was 
reverse-transcribed in a 20 µL reaction containing 1 µL of 0.5 µg/µL random hexamers 
(Invitrogen, Carlsbad, CA), 1 µL of 0.1 M dithiothreitol (DTT), 1 µL of 20 mM dNTP, 
and 1 µL of 200 U/µL RNase H- Superscript II reverse transcriptase (Promega, Madison, 
WI) buffered by 4 µL 5X First Strand Buffer (Promega).  Reaction samples were 
incubated at room temperature for 15 min to allow random priming.  Samples were then 
incubated for 1.5 h at 37ºC, followed by a 95ºC incubation for 3 min to inactivate the 
reverse transcriptase enzyme.  cDNA was precipitated overnight at -20ºC in 300 µL of 
100% ethanol and 2 µL of 3M sodium acetate, pH 5.2.  Samples were then centrifuged at 
16,000 x g for 10 min at 4ºC, supernants aspirated, and the cDNA pellets washed with 
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300 µL of 75% ethanol.  Samples were again centrifuged at 16,000 x g for 10 min at 4ºC.  
Following centrifugation, supernants were aspirated, samples pulsed, and the remaining 
ethanol aspirated using a 200 µL pipet tip.  cDNA were then dried in a tissue-culture 
hood and suspended in 50 µL of DEPC-treated H2O. 
Semi-quantitative Reverse Transcription – PCR 
 Polymerase chain reaction (PCR) was performed on 2% of the reverse-transcribed 
cDNA product to quantify expression of the steady-state mRNAs.  The reaction mixture 
consisted of 1.0 µL cDNA, 20 µL DEPC-treated H2O, 1.0 µL of each primer (0.5 ug/µL), 
and 25 µL of GoTaqGreen (Promega).   Samples were denatured for 5 min at 94ºC.  PCR 
was performed using 92ºC denaturation for 30 sec; annealing at 51ºC – 56ºC (α1(I) 
procollagen, 51ºC; α2(I) procollagen, 52ºC; G3PDH, 51ºC; αSMA, 55ºC; MMP-2, 56ºC; 
MMP-13, 56ºC; TIMP-1, 56ºC; TIMP-2, 52ºC; Smad3, 52ºC; Smad7, 50ºC; TGF-β, 
52ºC); and extension at 72ºC for 30 sec with the final extension extended to 5 min using a 
Techne TC-512 Thermal Cycler (Techne Incorporated, Burlington, NJ).  The total 
number of cycles varied (20-30) to ensure PCR products were in the linear range.  
Primers used in reactions are listed in Table 1.  PCR products were subjected to 
electrophoresis in a 2% agarose (Fisher Scientific, Hampton, NH) buffered with 0.5X 
TAE pH 8.0 (0.04M Tris – acetate, 0.001M EDTA).  Bands were visualized by UV 
transillumination using a Biospectrum AC Imaging System (UVP, Upland, CA).  
Relative expression,determined by band densitometry, was performed using Quantity 
One software (Bio-Rad, Hercules, CA).   
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Quantitative Reverse Transcription – PCR 
 Quantitative (Real-Time) Polymerase chain reaction was performed on 2% of the 
reverse-transcribed cDNA product to more accurately quantify expression of the steady-
state mRNAs encoding α1(I) procollagen, α2(I) procollagen, matrix metalloproteinase-2 
(MMP-2), tissue inhibitor of matrix metalloproteinase-2 (TIMP-2), and glyceraldehyde 3-
phosphate dehydrogenase (G3).  The reaction mixture consisted of 1.0 µL cDNA, 5 µL 
DEPC-treated H2O, 1.0 µL of each primer (5 µM), and 5 µL SYBR Mix (Qiagen, Hilden, 
Germany).   Reactions were also prepped in the absence of template cDNA to detect any 
contamination for each primer pair.  Samples were loaded into reaction capillaries and 
centrifuged in a LC Carousel Centrifuge 2.0 (Roche, Basel, Switzerland). 
 For each primer pair, a cDNA sample positive for the target product was serilly 
diluted and subjected to amplification using a LightCycler 1.5 (Roche) for 50 cycles 
along with the experimental samples to permit calculation of the efficiencies (E) of the 
amplifications.  Relative message levels of each target gene product was determin d by 
normalizing the target gene crossing point (Cp) to the Cp of the housekeeping gene 
G3PDH using the formula: relative expression ratio = (Etarget 
∆CPtarget (control – sample) / 
(Ereference 
∆CPreference (control – sample) [213]. 
Immunoblot analysis 
 Cultured HSCs were washed with PBS and whole-cell extracts (WCEs) were 
prepared with radioimmunoprecipitation assay (RIPA) buffer (1% NP-40, 0.5% 
deoxycholate, 0.1% SDS, 0.5 mM phenylmethylsulfonyl fluoride (PMSF), 0.05 mM 
Na3VO4, 2 µg/mL aprotinin, in phosphate-buffered saline (PBS)).  Nuclear proteins were 
prepared using the NE-PER kit (Pierce Biotechnology, Rockford, IL) according to the 
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manufacturer’s protocol.  Protein concentrations were determined using the Bradford 
method (BioRad Laboratories, Hercules, CA [214].  Protein samples (10-25 µg per lane) 
were boiled in an equal quantity of 2X Sample Buffer (0.125 M Tris base, 20% glycerol, 
0.2% (w/v) sodium dodecyl sulfate, 0.2% (v/v) 2-mercaptoethanol, 0.02% (w/v) 
bromphenol blue, pH 6.8) and applied to standard 10% SDS polyacrylamide gels.  After 
electrophoresis, proteins were transferred to nitrocellulose membranes (Schleicher and 
Schuell, Keene, NH) using a transblot apparatus.  The membranes were stained with 
0.5% Ponceau S solution to assure equal protein loading and transfer.  The membranes 
were blocked using 5% non-fat milk in Tris-buffered saline (TBS, 25 mM Tris pH 8.0, 
144 mM NaCl) containing 0.05% (v/v) Tween-20 (TBS-Tween) at 25oC for > 1 h.  
Afterwards, the membranes were incubated at 4oC with primary antibodies for > 12 h.  
Primary antibodies utilized are listed in Table 2.  Primary antibodies were diluted 1:1000 
in 5% non-fat milk in TBS-Tween.  Membranes were then washed three times for 10 min 
with TBS-Tween.  After washing, the membranes were incubated with either goat anti-
rabbit IgG-HRP (Santa Cruz Biotechnology), donkey anti-goat IgG-HRP, or goat anti-
mouse IgG-HRP (Santa Cruz Biotechnology) at a dilution of 1:5000 in 5% non-fat milk 
at 4oC for 1 h.  The membranes were then washed three times for 10 min in TBS-Tween 
and developed using the SuperSignal West Pico Chemiluminescent Substrate kit (Pierce).  
To visualize bands, membranes were then exposed to x-ray CL-Xposure Film (Thermo 
Scientific, Rockland, IL) and developed using a Mini Medical film developer (AFP 
Imaging, Elmsford, NY).  Relative protein expression was determined by band 
densitometery utilizing Quantity One software. 
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Transient Transfections and Reporter Assays 
NIH 3T3 fibroblasts were cultured in DMEM supplemented with 10% FCS, 2mM L-
glutamine, 100 units penicillin/mL, 0.1 mg/mL streptomycin, and 0.25 µg/mL 
amphotericin B in a 95% air-5% CO2-humidified atmosphere.  NIH 3T3 cells were 
seeded into 6-well dishes at a density of 4.5 x 105 cells per well.  The day after seeding 
0.5 µg of pRSV-β-gal (Promega) and 0.5 µg of pNF-κB 3XLUC [215] were co-
transfected using 11 µg of LipofectAMINE (Invitrogen) per well for 8 h in serum-free 
media.  Follwing transfection, media was aspirated and replaced with growth media
overnight to allow cells to recover.  Cells were then serum-starved for 24 h and 
subsequently treated in the presence or absence of 250 - 1000 µM SAMe for 24 h. In 
experiments to block p38-MAPK activity, cells were pretreated with either DMSO or  
5 µM SB203580 for 30 min prior to treatment with SAMe.  Following incubation, cells 
were washed gently with 1X PBS and lysed by adding 80 µL of 1X Reporter Lysis Buffer 
(Promega) to each well.  Cells were scraped, transferred to a 1.5 mL microcentrifug  
tube, and subjected to freeze/thaw at -70ºC.  Lysates were then centrifuged at 16,000 x g 
and supernants transferred to fresh tubes.  Samples were diluted 1:10 in Reporter Lysis 
Buffer and luciferase activity was determined by incubating 1 µL of sample in 100 µL of 
Luciferase Reporter System solution (Promega).  Luciferase activity was then 
immediately determined using a TD-20/20 Luminometer (Turner BioSystems, 
Sunnyvale, CA).  Values were recorded as the average of two readings.   
To normalize for transfection efficiency, β-galactosidase activity was determined.  
Extracts were prepared as with the Luciferase assay and 30 µL of extract was added to 
790 µL of sodium phosphate buffer (87.5 mM sodium phosphates, 1 mM MgCl2, and 
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0.8% β-mercaptoethanol) and 200 µL 4 mg/mL ortho-nitrophenyl-β-galactosidase. 
Samples were incubated at 37ºC for 2 h in semi-microcuvettes.  Following incubation  
β-galactosidase activity was determined by reading A410 using a DU 650 
Spectrophotometer (Beckman). 
Adenoviral Infection of HSCs 
The recombinant replication-deficient adenoviruses Ad5IκB and Ad5GFP were 
generously supplied as a gift from Dr. David Brenner and have been described [216].  
Rat-1 fibroblasts were cultured in DMEM supplemented with 10% FCS, 2mM L-
glutamine, 100 units penicillin/mL, 0.1 mg/mL streptomycin, 0.25 µg/mL amphotericin B 
in a 95% air-5% CO2-humidified atmosphere.  Cells were seeded into 6-well dishes at a 
density of 5.0 x 105 cells per well.  The following day cells were infected with either 
Ad5IκB or Ad5GFP at an MOI of 300 for 6 h in 2.0% FCS media.  Cells were allowed to 
recover > 12 h in 10% FBS media following infection.  The cells were then serum-
starved for 24 h in media with serum reduced to 0.5% FBS.  Cells were then treated in the 
presence or absence of 1 mM SAMe for 12, 24, and 48 h.  After each time point WCEs 
were prepared using RIPA buffer.  To ensure sufficient adenovirus infection efficacy, 
cells were viewed under an IX71 fluorescent microscope (Olympus, Central Valley, PA) 
using the fluorescein isothiocyanate (FITC) filter to determine the population of green 
fluorescent protein- (GFP) expressing cells.  
 Co-Immunoprecipitation 
Cultured HSCs were washed with PBS and WCEs were prepared with RIPA 
buffer.  Protein samples (200-250 µg) were incubated overnight at 4°C with 2 µg rabbit 
anti-type I collagen (Rockland, Gilbertsville, PA).  This antibody has been previously 
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shown to bind to pro-α1(I) chain, the mature α(I) chain, and the heterotrimer of type I 
collagen, but does not recognize α2(I) chain.  Immune complexes were precipitated by 
incubation with Protein A/G agarose beads for 6 h.  Precipitated complexes were washed 
3 times with RIPA buffer and stored in 2X Sample Buffer.  Immunocomplexes were 
analyzed by 10% acrylamide gel followed by transfer to nitrocellulose.  Immunoblot 
analysis and detection was performed using mouse anti-polyubiquitin IgM (Biomol, 
Plymouth Meeting, PA) diluted 1:1000 and goat anti-mouse IgM (Santa Cruz 
Biotechnology) diluted 1:2000. 
p38 MAPK Assay 
 All reagents and instructions were provided by the p38 MAPK Assay Kit (Cell 
Signaling).  Culture-activated HSCs plated on p100 dishes were pretreated with 0, 500, 
1000, or 2000 µM SAMe for 30 min.  Cells were then treated for 30 min in the presence 
or absence of 200 µM acetaldehyde (Sigma-Aldrich) at 37ºC in a CO2 incubator.  Plates 
were wrapped with parafilm to prevent loss of acetaldehyde.  Cell lysates wer  then 
collected using 0.5 mL of cold 1X Cell Lysis Buffer.  Cells were scraped and trsferred 
to a 1.5 mL microcentrifuge tube.  Cells were subjected to 3 cycles of freeze-thaw for 5 
min each utilizing the -70ºC freezer.  Samples were then microcentrifuged for 10 min at 
4ºC and the supernants transferred to new 1.5 mL microcentrifuge tubes.  phospho-p38 
MAPK was then precipitated by incubation with 20 µL of immobilized antibody Bead 
Slurry overnight at 4ºC.  Immune complexes were then centrifuged for 30 seconds at 
14,000 x g at 4ºC.  Pellets were washed two times with 500 µL of cold 1X Cell Lysis 
Buffer followed by repeated centrifugation.  Pellets were then suspended in 50 µL of 1X 
Kinase Buffer supplemented with 200 µM ATP and 1 µL of ATF-2 Fusion Protein.  
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Samples were incubated for 30 min at 30ºC.  Following incubation, reactions were 
stopped with the addition of 2X Sample Buffer and immunoblot analysis using an 
antibody recognizing phospho-ATF-2 (Thr71) was performed. 
Fluorescent Immunohistochemistry 
 Slides with paraffin-embedded sections were heated at 60ºC for 1 h.  Paraffin was 
removed by incubation in D-limonene three times for 5 min.  Sections were then re-
hydrated by successive incubation in 100% ethanol, 95% ethanol, 80% ethanol, and 
distilled H2O each twice for 5 min.  Following rehydration, sections were subjected to 
antigen capture.  Slides were placed in a rice cooker and steamed for 30 min in the 
presence of 10mM sodium citrate and 0.05% Tween 20.  Following incubation, slides 
were allowed to cool to room temperature for 20 min.  Sections were then incubated on 
ice with 1% NaBH4 diluted in PBS 3 times for 15 min.  Sections were then rinsed twice in 
PBS for 2 min followed by 5 min incubation in TBS-Tween.   
 Slides were then blocked at room temperature for 30 min with 5% goat serum and 
1% BSA diluted in TBS-Tween.  Sections were then incubated with primary antibody; 
rabbit anti-rat type I collagen (Rockland), rabbit anti-4-hydroxy-2-nonenal (Alpha 
Diagnostics, San Antonio, TX),  rabbit anti-polymorphonuclear leukocytes (PMNs) 
(Cederlane, Ontario, Canada), and mouse anti-polyubiquitin IgM (Biomol) diluted at 
1:100 overnight at 4ºC in a humidified environment.  Slides were then rinsed twice for 
two min with TBS-Tween and then incubated in secondary antibody; goat anti-rabbit IgG 
conjugated to AlexaFluor488 (Invitrogen) and goat anti-mouse IgM conjugated to 
AlexaFluor 594 (Invitrogen) diluted 1:100 for 1 h at room temperature in a humidified 
environment protected from light.  Sections were then washed three times for 10 min 
51 
 
with TBS-Tween.  Slides were then incubated with 4',6-diamidino-2-phenylindole 
(DAPI) at a concentration of 21 µg/mL for 5 min in the dark.  Subsequently, slides wer 
washed 3 times 5 min in PBS and mounted with ProLong Antifade Gold (Invitrogen) 
before covered with glass coverslips.  Slides were allowed to cure at room temperature 
for 24 h prior to image capture.  Images were captured with an Olympus fluorescent 
microscope using DAPI, FITC, and Texas Red filters.  Five fields per section were 
captured using each filter at both 10X and 20X magnifications.  For co-localization 
studies, captured images were merged utilizing Image Master (Photon Tech ology 
International, Birmingham, NJ) and the total amount of overlap and the ratio of overlap to 
FITC-positive areas was calculated. 
Ethanol Assay 
 Reagents were obtained from the QuantiChrom Ethanol Assay Kit (BioAssay 
Systems, Hayward, CA).  Serum was deproteinated with 2 volumes of 10% 
tricholoracetic acid.  Samples were centrifuged for 5 min at 14,000 x g at 4ºC and 
supernants were transferred to fresh tubes.  Ethanol standards were prepared in duplicate 
from a 2 mL stock solution of 10% ethanol (v/v) ranging from 0% to 2% with a total 
volume of 150 µL per standard.  For each experimental sample, 150 uL of deproteinated 
serums was used in triplicate.  To each standard and experimental sample, 100 uL of 
Reagent A was added using a multi-channel pipettor in a 96-well plate.  Samples were 
incubated at room temperature for 30 min.  Following incubation, 100 uL of Reagent B 
was added to each sample using a multi-channel pipettor.  OD580 was then determined 
using a Bio-Rad 550 Microplate Reader.   
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Alanine Aminotransferase Assay 
 Alanine Aminotransferase (ALT) was determined using standards and reagents 
from Pointe Scientific (Lincoln Park, IL).  ALT reagents were warmed to 37ºC prior to 
use.  To each well of a 96-well microplate, 10 uL of standard or experimental sample 
were added.  100 uL of ALT reagent was then added to each well using a multi-channel 
pipettor.  OD340 was determined every 1 min for 6 min at 37ºC using a Bio-Rad 550 
Microplate Reader.  Concentration change per minute was then determined by using 
minutes 2-4.  ALT was calculated by multiplying the concentration change per minute by 
6183.527. 
Glutathione Assay 
 Reagents were provided from the Glutathione Assay Kit (Cayman Chemical 
Company, Ann Arbor, MI).  50 mg liver tissue was sonicated in 2 mL ice-cold 1X MES 
buffer (0.2M 2-(N-morpholino)ethanesulphonic acid, 0.05 M phosphate, 1 mM EDTA, 
pH 6.0).  Samples were centrifuged for 15 minutes at 10,000 x g at 4ºC.  Supernants were 
transferred to new tubes and deproteinated with an equal volume of 10 % metaphosphoric 
acid.  Samples were then vortexed and incubated for 5 min at room temperature followed 
by centrifugation at 2,000 x g for 2 min at room temperature.  Supernants were collected 
and transferred to new tubes.  Assay Cocktail was prepared using 11.25 mL 1X MES 
Buffer, 0.45 mL Cofactor Mixture, 2.1 mL Enzyme Mixture, 2.3 mL H2O, and 0.45 mL 
of DTNB.  Immediately prior to assaying, 50 µL of 4M triethanolamine was added per 1 
mL of sample.  50 µL of standard or 50 µL of experimental sample were added to each 
well of a 96-well plate.  All standards and experimental samples were assayed in 
duplicate.  150 µL of Assay Cocktail were then added to each well and OD405 was 
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measured following 25 min incubation at room temperature in a dark environment.  For 
determination of GSSG, the same procedure was followed; however, 10 uL of 2-
vinylpyridine was added to each standard and experimental sample 60 minutes prior to 
the addition of Assay Cocktail.  GSH and GSSG levels were normalized for amount of 
tissued initially used and expressed as µM/g.  GSSG/GSH was calculated by dividing the 
concentration of GSSG by the concentration of GSH for a particular sample. 
Statistical Analysis 
In vitro experiments were performed at least in triplicate.  Data are presented as 
mean ± SEM.  Student’s t-test (parametric) or the Mann-Whitney Rank Sum Test (non-
parametric) was performed for paired data.  One or two-way ANOVA (paramet ic) or 
ANOVA on the Ranks was performed on unpaired data.  Post-hoc analysis depended on 
the comparisons being made.  SigmaStat version 2.0 was utilized for all statistical 
analysis with a P value of less than 0.05 considered significant. 
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Table 1.  PCR forward and reverse primers. 
Target Product size Primers 
α1(I) procollagen 269 b.p. 5’-CACTGCAAGAACAGCGTAGC-3’ 
5’-ATGTCCATTCCGAATTCCTG-3’ 
α2(I) procollagen 286 b.p. 5’-AAGGCATTCGAGGACACAAC-3’ 
5’- TTACCAACAGGCCCAAGTTC-3’ 
G3PDH 292 b.p. 5’-ATCCCGCTAACATCAAATGG-3’ 
5’- ACTGTGGTCATGAGCCCTTC-3’ 
αSMA 446 b.p. 5’-GCTGGACTCTGGAGATGGCGTGAC-3’ 
5’- CCCGAGAGGACGTTGTTAGCATAG-3’ 
MMP-2 290 b.p. 5’-ACACTGGGACCTGTCACTCC-3’ 
5’-AGTGGCTTGGGGTATCCTCT-3’ 
MMP-13 290 b.p. 5’-GCATACGAGCATCCATCCCGAGAC-3’ 
5’- GCATCTACTTTGTCGCCAATTCC-3’ 
TIMP-1 309 b.p. 5’-GCCATGGAGAGCCTCTGTGG-3’ 
5’-GCAGGCAGGCAAAGTGATCG-3’ 
TIMP-2 250 b.p. 5’-GCATCACCCAGAAGAAGAGC-3’ 
5’-GGGTCCTCGATGTCAAGAAA-3’ 
TGF-β 282 b.p. 5’-GCAACAACGCAATCTATGACA-3’ 
5’-TGATTTCCACGTGGAGTACAT-3’ 
Smad3 297 b.p. 5’-GTGACACTCCTGAAGGCCATAC-3’ 
5’-GGCCAACAAAGAGGGTTCTAGT-3’ 
Smad7 276 b.p. 5’-TCCTTACTCCCAGATACCGATG-3’ 
5’-TGACTCTTGTTGTCCGAATTGA-3’ 
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Table 2.  Antibodies used for immunoblot analysis. 
Antibody Host Specificity Manufacturer 
anti-type I collagen Rabbit Rat Biodesign 
anti-αSMA Mouse Human DAKO 
anti-IκBα Rabbit Human Cell Signaling 
anti-p65 Rabbit Human Chemicon 
anti-PDI Goat Human Santa Cruz 
anti-grp78 Goat Human Santa Cruz 
anti-β-actin Goat Human Santa Cruz 
anti-HA Mouse Human Sigma 
anti-CYP2E1 Rabbit Human Chemicon 
anti-ADH Rabbit Mouse Santa Cruz 
anti-ALDH Goat Human Santa Cruz 
 
CHAPTER 3: EFFECTS OF S-ADENOSYL-L-METHIONINE ON  
TYPE I COLLAGEN 
 
 
Introduction 
 Hepatic fibrosis remains a significant health problem throughout the world.  In 
Africa and Asia, viruses and parasites are the principal cause of fibrosis, whereas in 
Europe and the United States chronic excessive ethanol consumption is the underlying 
cause for the majority of cases.  Because liver fibrosis is defined by theaccumulation of 
excess extracellular matrix components, principally type I collagen, th rapies that 
decrease the production, or stimulate the breakdown, of type I collagen are of interest. 
 To date a number of therapeutic agents have been evaluated in both animal 
models and human clinical trials as treatments for hepatic fibrosis.  Colchicine, an 
alkaloid derived from Colchicum autumnale, is a compound best known for its effects as 
an antimitotic agent.  It has also been shown to possess anti-inflammatory and 
hepatoprotective properties [217-219].  In humans, colchicine was shown to prolong 
survival in patients with alcoholic cirrhosis.  However, a follow up study examining the 
results of 14 randomized clinical trials demonstrated no significant improvement [220].  
The use of colchicines is further compounded by the toxicity associated with its 
administration and thus must be given at low doses to prevent adverse effects.   
 Another class of drugs that has received interest as a therapy for hepatic fibrosis is 
the corticosteroids.  These compounds have been shown to decrease inflammation in 
alcoholic hepatitis, reduce production of cytokines, mitigate formation of acetaldehyde 
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adducts, and diminish type I collagen production [221].  Short term survival was also 
increased in patients with severe alcoholic hepatitis [222].  However, a systematic review 
of trials utilizing corticosteroids was unable to identify any significant beefit on liver 
histology, frequency of liver complications, or liver-related mortality [223]. 
 Because hepatic fibrosis is often associated with oxidative stress, therapies 
utilizing antioxidants as treatments have received much attention.  Silymarin, a mixture 
of four flavonoids isolated from the milk thistle plant (Silybum marianum), has been 
noted for centuries as a treatment for liver diseases [224].  Silymarin has been hown to 
possess antioxidant, anti-lipid peroxidative, and anti-fibrotic properties and could prevent 
injury in a CCl4 intoxication model of fibrosis [225, 226].  However, when silymarin was 
used as a treatment for established CCl4-induced fibrosis, no positive effect was seen, 
suggesting silymarin may be more effective as a preventative therapy for hepatic fibrosis 
than a reversing agent [227].  This pattern was also present in human clinical trials where 
silymarin was beneficial in several studies examining management of early liver injury 
but no positive pathological benefit was seen when silymarin was used in patients with 
alcoholic cirrhosis [228-230].  Thus, it is important to determine the clinical settings in 
which a particular treatment may be beneficial; prevention of hepatic fibrosis vs. 
resolution of hepatic fibrosis. 
 Another antioxidant that has received attention as a potential therapy for hepatic 
fibrosis is resveratrol, a phytoalexin (a class of antibiotics produced in plants) naturally 
found in grapes and commercially in red wine.  Resveratrol exhibits anti-inflammatory 
properties, anti-oxidant effects, and modulates metabolism of lipids [231].  In a CCl4-
mediated model of fibrosis, resveratrol prevented fibrosis with concomitant inhibiton of 
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NF-κB translocation and attenuation of TGF-β production [232].  Inhibition of NF-κB by 
resveratrol was also reported in vitro along with a decrease in proinflammatory cytokine 
production [233, 234].  There is however a lack of human studies examining the efficacy 
of resveratrol as a treatment for liver disease. 
 S-adenosyl-L-methionine (SAMe) is an endogenous molecule that participates in 
a large number of reactions in the liver and is important in maintaining liver health.  
SAMe levels are reported to decrease in a number of liver injury models, and 
supplementation with exogenous SAMe prevents depletion of GSH, the principal 
intracellular antioxidant, suggesting a role for SAMe as an antioxidant therapy [235, 
236].  In numerous animal models, SAMe has been shown to attenuate fibrosis and also 
decrease neoplastic nodules in models of liver cancer [200, 210, 237, 238].  An analysis 
of clinical studies utilizing SAMe in human patients suggested SAMe does not have an 
effect on alcoholic liver disease compared to placebo [239].  The authors commented; 
however, that the quality of the studies reviewed varied and further clinical studies are 
necessary before concluding whether SAMe is an effective treatment for ALD.  Studies 
in patients with non-alcoholic liver disease did receive benefit from SAMe 
administration.  A well-conducted study utilizing SAMe in cirrhotic patients resulted in a 
significant decrease in mortality [209].  Additionally, SAMe appears to attenuate 
cholestatic liver disease [239].  In vitro studies utilizing SAMe have focused on HSCs 
that have been culture-activated for less than 7 days.  These studies revealed SAMe 
decreases type I collagen production in HSCs with attenuation of TGF-β signaling [240, 
241]. 
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 The most widely-accepted model for mimicking activated HSCs during hepatic 
fibrosis is culture-activation on plastic for 14 days.  Because previous studies have 
focused on experiments with early-activated HSCs, there is a need to examine the eff cts 
of SAMe on later stages of culture-activated HSCs.  Based on data generated from 
previous studies utilizing SAMe and other antioxidants in HSCs, we hypothesized that 
SAMe inhibits type I collagen production in culture-activated HSCs by ameliorating the 
effects of oxidative stress through attenuation of NF-κB activity.  
Results 
SAMe attenuates type I collagen protein expression in activated HSCs. 
 Recent findings [240] have demonstrated SAMe decreases type I collagen 
expression in early cultures of primary HSCs.  However, HSCs do not fully trans-
differentiate into their activated myofibroblast-like phenotype until 14 days of culture. 
This results in an 80-fold increase in type I collagen expression and is considered a 
suitable in vitro model for hepatic fibrosis.  To determine the effect of SAMe on type I 
collagen in culture-activated HSCs, cells were treated with 250, 500, or 1000 µM SAMe 
for 6, 12, and 24 h.  Cell viability was >95% following all treatments as determined by 
Trypan Blue exclusion.  SAMe treatment attenuated intracellular type I collagen protein 
expression in a time and dose-dependent manner with the maximum effect being 24 h of 
treatment with 1000 µM SAMe (Fig. 8).  One-way ANOVA analysis revealed, however, 
that the decrease in intracellular type I collagen expression was not statistically 
significant compared to untreated cells. 
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SAMe significantly decreases type I collagen protein secretion in activated HSCs. 
 Since hepatic fibrosis is the result of excessive deposition of extracellular matrix 
products, principally by the HSCs, the effects of SAMe treatment on the secretion of ype 
I collagen into culture media was evaluated.  Following treatment for 12 and 24 h with 
1000 µM SAMe, media was collected, concentrated, and analyzed for type I collagen 
content by Western blot analysis.  SAMe treatment resulted in a highly significant 
(p<0.001) decrease in type I collagen secretion into culture at 24 h as determined by 
Student’s t-test (Fig. 9). 
αSMA mRNA expression is decreased by SAMe in activated HSCs. 
 The most widely used histological marker for hepatic fibrosis in humans is αSMA 
expression, a marker for HSC activation.  To determine if SAMe can inhibit 
acetaldehyde-mediated increases in αSMA expression in culture-activated HSCs, cells 
were pretreated for 30 min with 0, 250, 500, 1000, or 2000 µM SAMe.  Cells were then 
treated for 12, 24, and 48 h with 200 µM acetaldehyde, a metabolic by-product of ethanol 
metabolism.  Screw-top T25 tissue culture flasks were used to prevent evaporation f 
acetaldehyde.  RT-PCR for αSMA showed addition of acetaldehyde increased αSMA 
expression compared to control, most notably at 12 h.  Treatment with SAMe showed a 
slight decrease in acetaldehyde-mediated increases in αSMA expression at only 12 h. 
There was also a dose-dependent decrease in αSMA expression at 24 and 48 h (Fig. 10). 
NF-κB activity is upregulated by SAMe in HSCs. 
Many antioxidants have been shown to downregulate the redox-sensitive 
transcription factor NF-κB in activated HSCs.  It was hypothesized that SAMe would 
decrease NF-κB activity in SAMe-treated HSCs.  However, increasing doses of SAMe 
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resulted in significantly-increased translocation of the p65 subunit of NF-κB to the 
nucleus following 1 h of treatment of culture-activated of HSCs (Fig. 11).  Treatment 
with 100 ng/mL of LPS was used as a positive control for the translocation of p65.  To 
determine if SAMe treatment also increased binding of NF-κB, EMSA was performed.  
SAMe treatment increased retention of labeled probe containing the NF-κB consensus 
sequence (Fig. 12).  Utilization of antibodies to the p50 and p65 subunits of NF-κB
resulted in further retention of the complex, suggesting increased binding of the p65/p50 
complex in activated HSCs.  To determine if the increases in NF-κB were associated with 
degradation of IκBα, immunoblot analysis was performed on Rat-1 fibroblasts, a type I 
collagen-producing cell-line, and culture-activated HSCs treated with either 0, 500, or 
1000 µM SAMe for 15, 30, and 60 min.  Treatment with SAMe resulted in a decrease in 
IκBα (Fig. 13) expression with degradation appearing greater in Rat-1 fibroblasts th n 
HSCs.  To evaluate NF-κB transcriptional activity, transient transfections of an NF-κB-
responsive luciferase plasmid were performed utilizing NIH 3T3 fibroblasts, a readily-
transfectable, collagen-producing mouse cell-line.  Following 24 h of treatment with 250, 
500, or 1000 µM SAMe there was a significant increase in luciferase activity with the 
500 and 1000 µM doses of SAMe, suggesting an increase in transcriptional activation by 
SAMe (Fig. 14).  To evaluate if SAMe-dependent stimulation of NF-κB transcriptional 
activation was dependent on p38 MAPK, a known phosphorylator and activator of NF-
κB, the specific p38 MAPK inhibitor SB203580 was used.  SB 203580 inhibits p38 
MAPK activity by competitively inhibiting binding of ATP, preventing kinase activity.  
The increase in SAMe-dependent NF-κB transcriptional activation was abolished at the 
1000 µM dose when pre-treating for 30 min with 5 µM SB203580 (Fig. 14). 
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p38 MAPK activity is increased by SAMe in activated HSCs. 
 Because the SAMe-mediated increase in NF-κB-dependent transcriptional 
activation in NIH 3T3 fibroblasts appeared to be blocked with the addition of the specific 
p38 MAPK inhibitor SB203580, we examined the effects of SAMe on p38 MAPK 
activity in activated HSCs.  Cultured activated HSCs were pretreated with 0, 500, or 1000 
µM SAMe for 30 min followed by treatment with 200 µM acetaldehyde for 30 min.  
phospho-p38 MAPK was immunoprecipitated from lysates and kinase activity was 
determined by measuring phosphorylation of the p38 MAPK target, ATF-2.  No activity 
was seen in untreated cells and cells treated with acetaldehyde alone; however, there was 
a small amount of activity following 2000 µM SAMe treatment alone (Fig. 15).  Activity 
was enhanced by co-treatment of SAMe and acetaldehyde in a dose-dependent man r.   
NF-κB activity is required for SAMe-mediated type I collagen inhibition. 
Previous studies demonstrated that overexpression of the p65 subunit of NF-κB 
can inhibit transcriptional activation of α1(I) procollagen expression [109].  To 
investigate whether the observed increases in NF-κB activity had an influence on type I 
collagen protein levels, NF-κB activity was blocked utilizing an adenovirus that 
expresses a dominant-negative form of the IκBα regulatory protein.  Rat-1 fibroblasts 
were infected with either Ad5IκB, which was HA-tagged, or Ad5GFP (to serve as a 
control vector) at an MOI of 300.  HSCs were unable to be used for these experiments 
due to the observation that Ad5IκB-infected HSCs appeared to “round up” and detach 
from the tissue culture plates following SAMe treatment.  Following overnight recovery 
cells were serum-starved for 24 h.  SAMe was then added at 0, 250, 500, or 1000 µM 
concentrations for 24 h.  Whole-cell extracts were generated and immunoblot analysis for 
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type I collagen was performed.  In Ad5GFP (control) infected cells, SAMe significantly 
decreased type I collagen protein expression.  However, Ad5IκB-infected cells did not 
show a significant decrease in type I (Fig. 16), suggesting intact NF-κB signaling is 
necessary for SAMe to decrease type I collagen.  To verify infection and expression of 
Ad5IκB, immunoblot analysis was performed for HA.  Ad5IκB, but not Ad5GFP-
infected cells expressed HA (Fig. 16).   
SAMe does not affect α1(I) procollagen steady-state mRNA levels in activated HSCs. 
Previous findings have suggested SAMe decreases type I collagen expression in 
early cultures of HSCs by decreasing levels of α1(I) and α2(I) procollagen mRNA levels 
[240, 241].  Additionally, Rippe et al. reported overexpression of p65 decreased α1(I) 
procollagen gene expression in activated HSCs [120].  We hypothesized SAMe decreases 
type I collagen protein expression via transcriptional-inhibition of the α1(I) procollagen 
gene by increasing p65 nuclear translocation.  To examine this hypothesis steady- ate 
mRNA levels of α1(I) procollagen message were measured by RPA and RT-PCR.  
Culture-activated HSCs were incubated in 1000 µM SAMe for 6, 12, and 24 h, and total 
RNA were isolated.  Ribonuclease protection assay analysis revealed no significant 
change in steady-state mRNA levels of the α1(I) procollagen gene by SAMe (Fig. 17).  
Additionally, RT-PCR revealed no significant change in α1(I) and α2(I) procollagen gene 
steady-state mRNA levels (Fig. 18). 
SAMe stimulates polyubiquitination of type I collagen in activated HSCs. 
 Because SAMe did not decrease α1(I) and α2(I) procollagen gene steady-state 
mRNA levels, we examined the post-translation status of type I collagen.  We 
hypothesized SAMe targets type I collagen for degradation by the ubiquitin-proteasom  
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system (UPS), potentially by disrupting the normal folding and assembly of type I
collagen or transiently stimulating an ER stress response.  To examine the post-
translational fate of type I collagen, cultured HSCs were treated in thepres nce or 
absence of 1000 µM SAMe for 3, 6, 12, or 24 h and whole cell extracts were prepared 
following each time point.  Proteins complexed with type I collagen were 
immunoprecipitated and immunoblot analysis was performed against polyubiquitin. 
SAMe resulted in a slight increase in polyubiquitination of type I collagen at 3 h followed 
by a substantial increase at 6 and 12 h (Fig. 19).  By 24 h there was a dramatic decrease 
in polyubiquitination, potentially due to proteasomal degradation of polyubiquitinated 
procollagens.  Quantitation of results and densitometric analysis was limited by the high 
level of background on developed films. 
ER resident proteins are decreased by SAMe in activated HSCs. 
To determine a potential mechanism responsible for SAMe-mediated 
polyubiquitination of type I collagen, we examined the effects of SAMe on ER resident 
proteins involved in the folding, assembly, and processing of type I collagen.  Culture-
activated HSCs were treated in the presence of absence of 1000 uM SAMe for 3, 6, 12, 
and 24 h.  Whole cell lysates were collected and Western blot analysis was performed f  
Grp78, PDI, and Hsp47.  SAMe treatment resulted in no significant change in Hsp47 
levels.  Grp78 levels were slightly decreased by SAMe at 6 and 12 h and significantly 
decreased (P< 0.05) at 24 h as determined by Mann-Whitney Rank Sum Test.  Protein 
expression of PDI was unchanged by SAMe at 3, 6, and 12 h; however, there was a 
significant decrease in PDI expression at 24 h (P < 0.05) as determined by student’ t-test 
(Fig. 20). 
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SAMe does not increase polyubiquitination of type I collagen in a BDL model of 
hepatic fibrosis. 
 To determine if the stimulation of type I collagen polyubiquitination by SAMe is 
observed in vivo, a BDL model of experimental fibrosis was utilized.  Male Sprague-
Dawley rats were subjected to BDL or sham surgery.  One week post-surgery animals 
were treated with either 10 mg/kg of SAMe i.p. or an equal volume of saline as a vehicle.  
Treatments were given daily for 7 days.  At the end of two weeks, animals were 
sacrificed and tissues were harvested.  Immunofluorescence was performed on s ctions 
from paraffin-embedded slides.  Antibodies against type I collagen and polyubiquitin 
were detected using secondary antibodies conjugated to fluorescent probes.  Image 
capture and processing to generate merged images of staining against type I collagen and 
polyubiquitin revealed no co-localization, suggesting that in this model of experimental 
fibrosis SAMe does not stimulate polyubiquitination of type I collagen (Fig. 21). 
Discussion 
 SAMe is a candidate treatment for hepatic fibrosis as well other liver disease .  
Animal studies have shown SAMe can decrease fibrosis through a decrease in type I 
collagen accumulation [200, 210].  Clinical trials have also shown a benefit when using 
SAMe to treat ALD and cirrhosis; however, there is a lack of quality human studie to 
conclusively determine if SAMe is beneficial [209, 239].  Because in vitro studies 
detailing the effects of SAMe on HSCs focused on early-activated cells, we investigated 
the role of SAMe in type I collagen production by culture-activated (day 14) HSCs.  
Evaluating the efficacy of putative treatments for hepatic fibrosis, especially when 
targeting HSCs, is important due to the dramatic phenotype change that occurs during 
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transdifferentiation of HSCs.  Unpublished data by our laboratory demonstrated a marked 
change in the gene expression profiles of HSCs when comparing different days in culture.  
Thus, a treatment that inhibits collagen expression or prevents the onset of hepatic 
fibrosis may not necessarily be an appropriate agent for targeting established fibrosis or 
modulating activated HSCs. 
 Treatment with increasing doses of SAMe did not have a significant effect on 
intracellular type I collagen expression in HSCs, although there was a trend showing 
decreased levels in a dose-dependent manner at the 6 and 24 h time-points.  There was 
however, a significant decrease in type I collagen secretion at 24 h following treatment 
with 1000 µM SAMe.  This finding suggests SAMe may be an appropriate agent for 
targeting activated HSCs in hepatic fibrosis, since the main causative agent in liver 
fibrosis is excessive secretion of matrix components; specifically type I collagen.  In 
comparison to other studies utilizing SAMe in HSCs, there is a wide range of conditions 
and dosages used.  Nieto and Cederbaum treated early-cultures (up to day 7) of primary 
HSCs with 10 or 30 µM SAMe added daily in the absence of serum and observed a 
decrease in both type I collagen protein and α1(I) procollagen mRNA expression [240].  
Matsui and Kawada, however, used doses ranging from 100 µM to 10 mM in their 
experiments.  Primary HSCs were cultured for 24 h with 10% serum, and then cultured 
for 3 days with daily SAMe supplementation in the absence of serum, again seeing a 
decrease in α1(I) procollagen mRNA expression [241].  The normal intracellular 
concentration of SAMe is 60 µM, however, dosages up to 1.5 g/day are well tolerated in 
humans and this dosage would be approximately 500 µM upon absorption into the blood 
stream, thus we feel the concentrations used in the study are pharmacologically 
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appropriate [209, 242].  It is also important to note that the two studies were conducted 
largely in the absence of serum.  HSCs are typically culture-activated for 14 days in 
media supplemented with 10% serum prior to experimentation to model the in vivo
phenotype during hepatic fibrosis, as serum provides growth factors necessary to drive
the transdifferentiation process (Schrum lab, unpublished data).  The studies by Kawada 
and Nieto were conducted on HSCs cultured 7 days or less with daily SAMe 
supplementation in the absence of serum.  Thus, these studies are more appropriate for 
evaluating SAMe as a preventative treatment for hepatic fibrosis by inhibit g the 
activation of HSCs, as opposed to utilizing SAMe as a curative agent in activated HSCs 
by reducing type I collagen expression.  The differences in experimental designs may 
also explain why Nieto et al. demonstrated a decrease in type I collagen exprssion with 
lower doses of SAMe, as they may have been working with cells that were less 
transdifferentiated than cells that have been culture-activated for 14 days in the presence 
of serum. 
 To examine whether treatment of SAMe could prevent acetaldehyde from 
increasing αSMA expression in culture-activated HSCs, cells were pretreated with SAMe 
followed by treatment with acetaldehyde for 12, 24, and 48 h.  Acetaldehyde was chosen 
instead of ethanol based on findings that suggest HSCs do not express relevant amounts 
of CYP2E1.  SAMe did not have a significant effect on αSMA expression at 12 h; 
however, there was a substantial decrease in steady-state mRNA levels following SAMe 
treatment at 24 and 48 h, dropping expression below the basal level of expression in the 
untreated groups.  These data suggest that SAMe may function to revert activated HSCs 
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back to the quiescent phenotype, as αSMA expression results in stress fiber formation 
and is considered a marker for HSC activation. 
 To investigate a potential mechanism for type I collagen inhibition in HSCs by 
SAMe, we examined the transcription factor NF-κB.  This transcription factor is 
increased in activated HSCs, and switches from predominantly p50/50 to p65/50 with this 
change typically associated with an increase in transcription.  Stimulation of NF-κB is 
linked to oxidative stress [243, 244], a key factor implicated in the progression of hepatic 
fibrosis.  SAMe administration has been shown to decrease NF-κB activity in other cell 
types [245] along with increasing levels of GSH, suggesting a decrease in oxidative stress 
[246].  These findings, along with the report of SAMe-mediated decreases in TGF-β in 
HSCs, a target of NF-κB, led us to hypothesize SAMe decreases NF-κB activity in 
culture-activated HSCs.  Surprisingly, treatment with SAMe for 60 min reveald a 
statistically significant dose-dependent increase in p65 translocation.  To examin  NF-κB 
binding activity, EMSA was performed utilizing a radiolabelled probe of the NF-κB 
consensus sequence.  SAMe treatment resulted in a dose-dependent increase in p65/50 
binding in extracts isolated from activated HSCs.  Concomitant with p65 translocation 
and binding was an increase in IκBα degradation following treatment with SAMe. 
 Because NF-κB translocation and binding alone does not result in transcriptional 
activation, we utilized an NF-κB responsive luciferase plasmid transfected in NIH 3T3 
fibroblasts.  This cell line was chosen for its ease of transfection, as primary HSCs and 
Rat-1 fibroblasts are difficult to transfect.  Treatment with SAMe caused a dose-
dependent increase in luciferase activity, suggesting that SAMe significantly increases 
NF-κB transcriptional activation.  Because p38 MAPK has been shown to phosphorylate 
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p65 [247-249], we examined the effect of blocking p38 MAPK on SAMe-mediated NF-
κB transcriptional activation using the specific inhibitor SB203580.  This resulted in a 
decrease in NF-κB transcriptional activation down to control levels.   Further analysis 
revealed SAMe stimulates phosphorylation of p38 MAPK in culture-activated HSCs.  
This suggests that p38 MAPK cross-talk with NF-κB is important for modulating p65/50 
transcriptional activation in SAMe-treated HSCs. 
 The role of NF-κB in HSCs is somewhat ambiguous.  Treatments that decrease 
NF-κB have been shown to improve hepatic fibrosis [232, 250, 251]; however, p65 is 
protective against fibrosis in hepatitis C infection [252], does not stimulate 
transdifferentiation of HSCs [118], and overexpression in HSCs can inhibit both α1(I) 
and α2(I) procollagen mRNA expression [120, 121].  This led us to revise our hypothesis 
that SAMe inhibited type I collagen expression through NF-κB-mediated transcriptional 
inhibition.    
 Utilizing an adenovirus that expresses a dominant-negative form of the NF-κB 
inhibitory protein, IκBα, NF-κB activity was blocked in Rat-1 fibroblasts.  Treatment 
with SAMe resulted in a significant decrease in type I collagen expression in control cells 
infected with Ad5GFP, however cells infected with Ad5IκBα showed no significant 
decrease in collagen expression when treated with SAMe.  This suggests SAMe is indeed 
inhibiting type I collagen production through an NF-κB mediated pathway.  These 
experiments could not be conducted in primary HSCs due to the observation that that 
inhibition of NF-κB followed by treatment with SAMe resulted in cell death. Because 
NF-κB enhances survival by resisting apoptosis in activated HSCs [118], it is possible 
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that treatment with SAMe stimulates pro-apoptotic pathways that are normally blocked 
by high p65 expression.   
 To determine if SAMe-mediated type I collagen expression is also inhibited at the 
mRNA levels, cultured-activated HSCs were treated with SAMe for 24 hours and steady-
state mRNA levels of α1(I) procollagen mRNA were assessed by RPA.  RT-PCR was 
also performed for both α1(I) and α2(I) procollagen mRNA levels.  Despite inhibition of 
collagen by SAMe at the protein expression level, there was no significant change in the 
steady-state mRNA levels of either α1(I) or α2(I) procollagen.   
Post-transcriptional regulation of procollagens were investigated next as a 
possible mechanism for SAMe-mediated type I collagen inhibition.  After transc iption, 
SAMe may be disrupting normal translation of procollagen mRNAs or perturbing the 
normal processing and folding of procollagen polypeptides, resulting in a decrease in 
secretion.  This later hypothesis would potentially account for why there was no 
significant decrease in intracellular type I collagen following SAMe treatment, but a 
highly significant decrease in secreted type I collagen.  To examine this possibility, 
culture-activated HSCs were treated in the presence or absence of 1000 µM SAMe for 3, 
6, 12, and 24 hours.  Immunoprecipitation of type I collagen complexes was performed 
and polyubiquitin was analyzed by immunoblot analysis.  SAMe treatment resulted in a 
substantial amount of polyubiquitination of type I collagen compared to untreated cells at 
6 h and peaking at 12 h before a marked decrease at 24 h.  This drop may be associated 
with type I collagen degradation by the 26S proteasome.  Unfortunately experiments to 
rescue the observed phenotype through inhibition of the 26S proteasome were 
71 
 
unsuccessful, as proteasomal inhibition results in apoptosis of activated HSCs as seen by 
other laboratories [253].   
 The processing and folding of procollagen polypeptides involves several ER 
resident proteins.  A decrease in any of these proteins by SAMe may perturb the normal 
processing of procollagen polypeptides and lead to unfolded or misfolded molecules.  
This would in turn trigger the UPS and lead to the degradation of improperly processed 
proteins by the 26S proteasome.  The ER resident proteins Hsp47, PDI, and Grp78 were 
assessed by Western blot analysis following treatment in the presence or absnce of 1000 
µM SAMe for 3, 6, 12, and 24 h.  There was no decrease in the collagen-specific 
chaperone Hsp47; however, there was a decrease in PDI at 24 h following SAMe 
treatment.  The kinetics of type I collagen polyubiquitination, however, may rule out 
involvement of PDI.  Grp78 levels following treatment with SAMe dropped immediately 
and reached their peak at 24 h.  This suggests Grp78 may be important in preventing the 
misfolding or misprocessing of procollagen polypeptides.  Decreases in Grp78 can lead 
to activation of PERK and Ire1, and transport of phosphor-ATF6, signaling the UPS.  
SAMe has also been shown in an animal model to correlate inversely with levels of 
Grp78 in the liver [254].   
 The redox status of the cell, and particularly the ER, plays an important role in ER 
stress and proper folding of nascent polypeptides.  Treatment of yeast with reducing 
agents such as DTT resulted in protein misfolding and a reduction in the amount of 
disulfide bonds [255].  The study also illustrated that under reducing conditions other 
secretory proteins that did not require disulfide bond formation were normally secreted, 
suggesting that selective retention of proteins requiring disulfide bond formatin may 
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occur during ER stress generated by changes in the redox state.  Although the 
mammalian ER is less oxidizing than the ER of yeast, the environment is still more 
oxidizing than the cytosol with a GSH:GSSG ratio of 3:1 in the ER as opposed to 100:1 
in the cytosol [256].  SAMe-mediated type I collagen inhibition may be occurring under
the same mechanism, as SAMe has been shown in vitro and in vivo to increase levels of 
reduced glutathione.  This may result in an increase in the pool of reduced PDI in the ER,
limiting its capacity to oxidize thiol groups to form disulfide bonds.  Reduction in PDI 
disulfide bond formation has been demonstrated in a reducing ER environment utilizing a 
model of alpha1-antitrypsin transgenic mice [257].  Thus, the identification of PDI 
inhibitors and mediators of a more reduced ER environment may represent a novel 
strategy for stimulating type I collagen degradation by the UPS without affecting the 
protein secretory pathway as a whole.  Future experimentation should focus on resolvi g 
the role of SAMe as either a direct antioxidant or antioxidant precursor.  Utilizing the 
methyltransferase inhibitor, ethionine, the conversion of SAMe to glutathione can be 
blocked, allowing for distinction between SAMe-specific effects and effects tha  arise as 
SAMe is converted to other compounds, such as glutathione.  These studies are 
complicated by the variety of reactions in which SAMe participates.  Inhibition of SAMe 
demethylation may drive the conversion of SAMe to MTA, which has also been shown to 
attenuate liver injury.  Thus, care must be taken when considering the contribution of 
SAMe and its many metabolites in determining mechanism of action. 
 To investigate if polyubiquitination of type I collagen occurred an animal model 
of hepatic fibrosis, a BDL model was utilized.  Following 1 week of either sham or BDL 
surgery, animals were treated with either 10 mg/kg SAMe or an equal volume of saline 
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by intraperitoneal injection daily for an additional 7 days.  Immunofluoresence was then 
performed to determine if there was any colocalization of polyubiquitin and type I
collagen in SAMe-treated animals.  Fluorescent microscopy revealed no colocalization of 
polyubiquitin and type I collagen.  Possibilities that may account for this observation 
include the BDL period prior to treatment was not long enough to fully activate HSCs or 
lack of sensitivity, since polyubiquitinated type I collagen would be found in HSCs, and 
the majority of collagen staining occurred in acellular areas.  Additionally, earlier time 
points should be examined prior to the degradation or downregulation of type I collagen. 
 These studies have helped elucidate the mechanisms of SAMe on culture-
activated HSCs.  Whereas previous studies have focused on SAMe as a preventative 
therapy by utilizing early-cultured HSCs, we focused on examining the role of SAMe as 
a reversing agent for fibrosis through the use of culture-activated HSCs.  Thee 
distinctions are important, as much of the morbidity associated with ALD is the refusal to 
cease consumption of ethanol.  Therapies that can successfully treat hepatic fibrosis in an 
environment where removal of the underlying etiology is not possible are desirabl for 
this reason.  Further experimentation to understand the precise molecular mechanisms of 
SAMe-mediated effects on culture-activated HSCs will help in our ability to determine 
the efficacy of SAMe in humans, as well as potentially lead to new therapeutic stra egies 
to augment mechanisms of action by SAMe to inhibit type I collagen production.  One 
particular approach may be the specific targeting of ER proteins to modulate coll gen 
expression in HSCs. 
  
 
74 
 
 
 
Figure 8.  SAMe attenuates type I collagen expression in activated HSCs. Culture-
activated (day 14) HSCs were treated with 0, 250, 500, or 1000 µM SAMe for 6, 12, and 
24 h.  Whole-cell extracts were isolated and immunoblot analysis was performed to 
analyze type I collagen expression.  Expression was normalized to β-actin (n=3). 
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Figure 9.  SAMe significantly decreases type I collagen secretion in activated HSCs.  
Culture-activated (day 14) HSCs were treated with 0 (C) or 1000 µM SAMe (S) for 12 
and 24 h.  Conditioned media was concentrated and immunoblot analysis was performed 
to analyze type I collagen secretion (n=4). 
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Figure 10.  αSMA steady
Culture-activated HSCs were pre
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Figure 11.  SAMe increases p65 nuclear translocation in activated HSCs.  Culture-
activated (day 14) HSCs were treated with 0 ( ! ,Ctrl), 250, 500, or 1000 µM SAMe for 
1 h.  Nuclear extracts were isolated and immunoblot analysis was performed.  LPS (100 
ng/mL) was used as a positive-control for p65 translocation (n=3). 
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Figure 12.  SAMe enhances NF-κB binding in activated HSCs.  Culture-activated (day 
14) HSCs were treated with 0, 250, 500, or 1000 µM SAMe for 1 hour.  Nuclear extracts 
were isolated and EMSA was performed.  To identify specific complexes, antibodies 
were utilized that recognize the p65 and p50 subunits of NF-κB (n=3). 
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Figure 13.  SAMe increases IκBα degradation.  Culture-activated (day 14) HSCs or Rat-1 
fibroblasts were treated with 0, 500, or 1000 µM SAMe for 15, 30, and 60 min.  Whole 
cell extracts were isolated and immunoblot analysis was performed using an atibody 
against IκBα.  β-actin was utilized as a control for protein sample loading (n=3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
β-actin
15 min 30 min 60 min
Rat-1
HSC
0 500 1000 0 500 1000 0 500 1000SAMe (µM)
IκBα
IκBα
80 
 
 
Figure 14.  NF-κB transcriptional activation is enhanced by SAMe.  NIH 3T3 fibroblasts 
were transfected with pNF-κB 3XLUC.  Cells were then treated for 24 h with 0 (Ctrl), 
250, 500, or 1000 µM SAMe (S).  To inhibit p38 MAPK activity, cells were pretreated 
for 30 min with 5 µM SB203580 (SB).  Lysates were used to determine luciferase 
activity (n=3).   
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Figure 15.  SAMe stimulates p38 MAPK activity.  Culture-activated HSCs were 
pretreated for 30 min with 0, 500, 1000, or 2000 µM SAMe.  Cells were then treated for 
30 min in the presence or absence of 200 µM acetaldehyde (Acet).   Immunoprecipitation 
of phospho-p38 MAPK (Thr180/Tyr182) was performed followed by incubation with a 
ATF-2 Fusion protein to evaluate kinase activity.  Western blot analysis was then 
performed using an antibody that recognized phosphorylated ATF-2 (n=3). 
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Figure 16.  NF-κB activity is required for SAMe-mediated type I collagen inhibition.  
Rat-1 fibroblasts were infected with either Ad5GFP (AdGFP) or HA-tagged Ad5IκBα 
(AdIκB) and treated in the presence (SAMe) or absence (CTRL) of 1000 µM SAMe for 
24 h.  Whole cell extracts were analyzed for type I collagen expression and normalized to 
β-actin expression.  To evaluate expression of dnIκBα, immunoblot analysis was 
performed for HA (n=3). 
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Figure 17.  α1(I) procollagen mRNA levels are not significantly affected by SAMe in 
activated HSCs.  Culture-activated HSCs were treated in the presence of 1000 µM SAMe 
for 0 (Ctrl), 6, 12, or 24 h. Ribonuclease protection assay was performed utilizing 
riboprobes for α1(I) procollagen, and GAPDH as a control.  Although SAMe increased 
steady-state mRNA levels of α1(I) procollagen mRNA this increase was not statistically 
significant. (M) Molecular weight standards (n=3). 
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Figure 18.  SAMe does not affect procollagen mRNAs in culture-activated HSCs.  
Culture-activated HSCs were treated with 0, 250, 500, or 1000 uM SAMe for 24 h. RT-
PCR was performed utilizing primers for α1(I) procollagen, α2(I) procollagen, and 
GAPDH as a control.  SAMe treatment had no effect on the levels of either procollagen 
(n=3). 
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Figure 19.  SAMe stimulates polyubiquitination of type I collagen in culture-activated 
HSCs.  Culture-activated HSCs were treated in the presence or absence of 1000 µM 
SAMe for 3, 6, 12, and 24 h. Coimmunoprecipitation of complexes recognized by an 
antibody to type I collagen was performed on lysates, and immunoblot analysis was 
conducted utilizing an antibody that recognizes polyubiquitin (n=3). 
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Figure 20.  ER resident proteins Grp78 and PDI are decreased by SAMe. Culture-
activated HSCs were treated in the presence or absence of 1000 µM SAMe for 3, 6, 12, 
and 24 h.  Whole cell lysates were prepared and analyzed by immunoblot analysis 
utilizing antibodies recognizing Grp78, PDI, and Hsp47.  Western blot analysis was also 
performed utilizing an antibody recognizing β-actin as a loading control (n=4). 
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Figure 21.  SAMe does not increase polyubiquitination of type I collagen in a BDL model 
of hepatic fibrosis.  Sprague-Dawley rat were subjected to either Sham or BDL surgery.  
Beginning on post-operative day 7 animals were treated with either 50 mg/kg SAMe or 
vehicle by i.p. injection daily for an additional 7 days.  Liver cross sections were co-
stained with antibodies recognizing type I collagen and polyubiquitin followed by 
detection with fluorescent-labelled secondary antibodies.  DAPI (blue) was used to 
indicate cell nuclei.  Type I collagen (green) was visualized with the FITC filter and 
polyubiquitin (red) was visualized with the TR filter  (n=8). 
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CHAPTER 4: ANIMAL MODELS OF HEPATIC FIBROSIS 
 
 
Introduction 
 In this section we describe the development of animal models of fibrosis that may 
be used to evaluate both the progression and treatment of hepatic fibrosis.  There remains 
a need to develop models of alcoholic fibrosis that are both easy to use and mimic the 
phenotype observed in human patients.  Thus we performed various durations of ethanol 
feeding coupled with LPS injections to evaluate a “two-hit” model of ethanol-induced 
hepatic fibrosis.  We also used a BDL model of hepatic fibrosis that results in rapid 
development of liver fibrosis, providing a means to test the efficacy of SAMe as a 
treatment for the resolution of fibrosis. 
Ethanol model of hepatic fibrosis 
 With a high prevalence of hepatic fibrosis and cirrhosis world-wide, there is a 
need to develop animal models that mimic the pathophysiology of human disease.  In 
particular, there remains a need to develop a clinically-relevant animal model of ethanol 
consumption that generates the peri-cellular fibrosis, and ultimately, “chicken-wir ” 
fibrosis seen in humans.  Despite the development of the nutritionally complete Lieber-
DeCarli (L-D) liquid ethanol diet that overcomes the natural aversion of rodents to 
ethanol consumption, ethanol alone does not lead to fibrosis, regardless of the length of 
administration [258].  L-D did, however, generate peri-venular steatosis, apoptosis, 
MEOS induction, reactive oxygen species, and glutathione depletion.   
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Increasing evidence points to a “two-hit” model of ethanol-induced fibrosis and a 
number of ethanol models have demonstrated fibrosis when augmented with a secondary 
stress such as iron [40] or vitamin A [36].  However, these secondary stresses are not 
considered clinically relevant to the majority of cases of ALD.  LPS is frequently 
observed to be elevated in patients with ALD [259].  Ethanol consumption disrupts the 
gut epithelium, allowing LPS leakage into the bloodstream [260].  LPS can interact with 
various liver cells such as the SECs, Kupffer cells, and HSCs to promote cytokine 
production and infiltration of inflammatory cells, which may ultimately lead to fibrosis.  
This position is further augmented by the observation that treatment of rodents with oral 
antibiotics lessens the damage due to ethanol intake [261]. 
In animal studies utilizing ethanol and LPS there is increasing evidence that LPS 
can enhance damage due to ethanol.  Mice maintained on an ethanol diet for 5 weeks 
followed by a one-time dose of LPS experienced greater fat accumulation, inflammatory 
cell infiltration, and hemorrhage than pair-fed controls [262].  In a model of chronic 
ethanol priming (2 weeks of ethanol feeding alone using a low carbohydrate/high fat diet) 
followed by 4 weeks of ethanol feeding with a continuous infusion of LPS, there were 
only minor histopathological changes; mainly polymorphonuclear cell infiltration [263].  
This suggests that continuous elevated endotoxin exposure may induce tolerance and 
desensitization of target cells, blunting the effects.  By utilizing an intragastric ethanol 
infusion model that provides continuous ethanol feeding (9 weeks) coupled with weekly 
5 mg/kg injections with LPS, Tsukamoto et al. showed centri-lobular fibrosis [264].  
Despite the ability to generate fibrosis in a model that may more closely mimic the 
progression of ALD in humans, the intragastric feeding model is limited by the invasive 
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nature of the intragastric feeding tube, requiring personnel trained in the surgery and 
maintenance of the feeding tube.  Also, this model does not represent the traditional 
delivery of ethanol through ad libitum consumption.   Thus, it would be beneficial to 
develop a “two-hit” animal model of liver fibrosis utilizing ethanol and LPS that is easy 
for investigators to utilize and more closely follows the normal pattern of ethanol 
consumption.  We hypothesized that utilizing the L-D ad libitum liquid ethanol diet 
coupled with weekly or biweekly injections of a mild dosage of LPS (0.5 or 1.0 mg/kg) 
would lead to hepatic fibrosis within 7 weeks. 
Materials and Methods 
7 week ethanol model of fibrosis pilot study 
 For the 7 week ethanol plus LPS (E. coli serotype 026:B6, Sigma) pilot study, 
male Sprague-Dawley rats weighing 200-250 g were used.  Animals were split into four 
groups: control (C), ethanol alone (E), ethanol plus weekly i.p. injections of 0.5 mg/kg 
LPS (EL 0.5), and ethanol plus weekly i.p. injections of 1.0 mg/kg LPS (EL 1.0) (n=3 for 
all groups).   
10 week ethanol model of fibrosis pilot study 
For the 10 week ethanol plus LPS pilot study, male Sprague-Dawley rats 
weighing 250-350 g were used due to an unanticipated delay in initiating the study.  
Animals were split into six groups: control (C), control plus 1.0 mg/kg LPS semi-wekly 
(L), control plus 10 mg/kg SAMe chloride (Sigma) injected i.p. every other day (S), 
ethanol alone (E), ethanol plus 1.0 mg/kg LPS injected i.p. semi-weekly (EL), and 
ethanol plus i.p. injections of 1.0 mg/kg LPS semi-weekly and 10 mg/kg SAMe chloride 
(ELS) every other day (n=3 for all groups). 
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8 week ethanol model of fibrosis pilot study 
For the 8 week ethanol plus LPS pilot study, male Sprague-Dawley rats weighing 
225-275 g were used.  Animals were split into five groups: control (C), control plus 10 
mg/kg SAMe toluene-sulfonate (Sigma) injected i.p. daily (S), ethanol alone (E), thanol 
plus 0.5 mg/kg LPS injected i.p. semi-weekly (EL), and ethanol plus i.p. injections of 0.5 
mg/kg LPS semi-weekly and 10 mg/kg SAMe toluene-sulfonate (ELS) daily (n=6 for all 
groups). 
Lieber-DeCarli liquid ethanol diet 
Animals were permitted ad libitum access to either an ethanol liquid diet (Lieber-
DeCarli Regular Ethanol, Dyets Inc., Bethlehem, PA) providing 36% of daily calories in 
the form of ethanol or an isocaloric control diet (Dyets Inc.) where calories p ovided by 
ethanol were replaced by dextrin-maltose.  To allow animals to acclimate to receiving 
ethanol liquid diets, the amount of ethanol in the diet was increased 25% every two days 
until receiving the full 36% of their calories from ethanol.  This time-point was 
designated as the start of the experiment.  To control caloric consumption of control rats, 
it was necessary to limit the amount of liquid control diet they received based on the 
average daily consumption across all ethanol groups.  Animals were weighed weekly to 
monitor weight gain.  At the conclusion of the feeding period (7 weeks, 8 weeks, or 10 
weeks), animals were sacrificed by exsanguination under anesthesia and tissues were 
collected.  Samples for histology were fixed for 20 hours in 10% neutral-buffered 
formalin, washed with tap H2O, and stored for processing in 70% ethanol.  Samples for 
protein and isolation of RNA were snap-frozen in liquid nitrogen.  Masson’s trichrome, 
Sirius red (except for the 8 week ethanol study, which was performed by Amel Karaa), 
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and hematoxylin and eosin (H&E) staining was performed by the image technician in the 
UNC Charlotte Department of Biology.  Examination of histological samples was 
performed by an investigator blinded to the study. 
Results 
Animal weights for the 7 week ethanol pilot study. 
 To monitor the weights of animals on the liquid control and ethanol diets, animals 
were weighed weekly.  Because the pilot study was conducted with the assistance of the 
laboratory of Dr. Mark Clemens, UNC-Charlotte, it was necessary conclude the 
experiment after 4 weeks for the C and E animals.  EL 0.5 and EL 1.0 animals were 
continued on the diet for 7 weeks.  For the first 4 weeks, animals in groups fed ethanol 
had similar weights while control animals had higher weights, despite consuming equal 
amounts of a nutritionally-complete isocaloric diet.  Following termination of the study 
for animals in the C and E groups, animals in the EL 0.5 and EL 1.0 groups had similar 
weights throughout the remainder of the study (Fig. 22).  One animal in the EL 1.0 group 
died two days after the 3rd i.p. LPS injection.  We suspected this was a consequence of 
injection error as opposed to mortality associated with the experimental conditions. 
 When comparing weight gain, there were broad differences.  EL 0.5 animals had 
the largest weight gain in the study (123.3 g ± 28.7), followed by C animals (120.7 g ± 
7.6) despite only being included in the study for 4 weeks.  Animals in the EL 1.0 group 
had a weight gain of 96 g ± 5.7 and E animals, which again were only subjected to 4 
weeks of liquid diet, had the smallest weight gain at 72 g ± 6 (Fig. 23).   
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Ethanol coupled with LPS injections induces early hepatic fibrosis. 
 To evaluate livers for fibrosis, Masson’s Trichrome staining was performed on 
sections from formalin-fixed livers.  There was minimal staining in C and E groups 
except around central veins and portal triads, as expected (Fig. 24).  Treatment with LPS 
resulted in mild fibrosis accumulating mostly peri-sinusoidally (Fig. 25).   
Animal weights for the 10 week Ethanol study. 
 To monitor the weights of animals on the liquid control and ethanol diets, animals 
were weighed weekly.  Animals in each group gained weight throughout the study, 
although animals in the ELS group initially gained weight at a slower rate in th  first two 
weeks of the study (Fig. 26).  Because there was a broad range of starting weights at the 
beginning of the study, weight change was evaluated.  Animals had a consistent amou
of weight gain over the course of the study.  Only animals in the ELS had a noticeably 
lower weight gain during the study (Fig. 27); however, this was not a statistically 
significant amount. 
Hepatic fibrosis was not induced by ethanol and LPS in the 10 week ethanol study. 
 Histological analysis following the 10 week ethanol study revealed only minor 
damage.  H&E staining of animals in the E group exhibited micro- and macrovesicular 
steatosis while addition of both LPS and LPS in conjunction with SAMe to ethanol-fed 
rats abolished this effect (Fig. 28).  In all groups normal liver architecture was preserved 
and there was no observable infiltration of inflammatory cells or areas of necrosis.   
 To assess if hepatic fibrosis was induced by 10 weeks of ethanol administration 
coupled with semi-weekly injections of 1.0 mg/kg LPS, Sirius red staining of formalin-
fixed sections was performed.  Surprisingly, there was no observable staining for 
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collagen in any group, except for small staining around vessels as normally found in the 
healthy adult liver (Fig. 29). 
Animal weights for the 8 week ethanol study. 
 To monitor the weights of animals on the liquid control and ethanol diets, animals 
were weighed weekly.  Animals in the control groups had higher weights throughout the 
study than animals in ethanol-fed groups (Fig. 30).  This trend was also evident in weight 
gain during the course of the study.  The highest weight gains were animals receiving 
control diets and there was a statistically significant difference it w ight gain between 
animals in the EL (194.6 g ± 6.2) and ELS (184 g ± 1.2) groups with animals in the S 
group (218.7 g ± 2.3) (Fig. 31).  
 Animals fed diets containing ethanol had detectable levels of ethanol ranging 
from 18 mM ±2.47 (EL) to 24.5 mM ± 4.53 (ELS) to 25.1 mM ± 2.28 (E) (Fig. 32).  
These levels correspond with blood alcohol contents of 0.11%, 0.14%, and 0.15% 
respectively, which in humans are suitable levels to cause motor impairment.  Ethanol 
consumption alone compared to control and control animals receiving daily SAMe 
injections resulted in a significant increase in liver:body weight ratio, suggestin  
hepatomegaly, an indicator of liver injury.  Animals receiving ethanol in combination 
with LPS semi-weekly, or ethanol and LPS semi-weekly in addition to daily SAMe 
administration also had hepatomegaly; however, this increase was not statistically 
significant (Fig. 33).   
Evaluation of ALT levels, a marker for hepatic injury, revealed significant 
damage caused by ethanol feeding and the combination of ethanol plus LPS compared to 
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control animals.  Treatment with SAMe significantly reduced hepatic injury as assessed 
by ALT levels (Fig. 34). 
Effects of SAMe on markers of oxidative stress. 
 The expression of key enzymes involved in the metabolism of ethanol and 
generation of oxidative stress were examined.  Ethanol consumption and ethanol coupled 
with LPS injections led to a significant increase in CYP2E1 expression.  This effect was 
attenuated significantly by treatment with daily SAMe (Fig. 35).  Levels of ADH were 
unchanged across all groups.  Expression of ALDH was significantly elevatd in animals 
fed ethanol and ethanol plus LPS (Fig. 35).  Treatment with SAMe slightly decreas d 
ALDH expression as compared to animals receiving ethanol plus LPS; however, this 
change was not statistically significant (Fig. 35). 
 To examine the effect on the redox status of livers from the ethanol diet, 
GSSG/GSH ratio was determined.  Animals from control and control plus SAMe groups 
showed low GSSG/GSH ratios, suggesting low levels of oxidative stress.  Consumption 
of ethanol significantly elevated the GSSG/GSH ratio, suggesting an increase in oxidative 
stress.  This ratio was further increased by consumption of ethanol with semi-weekly LPS 
injections.  Treatment with SAMe, however, restored normal GSSG/GSH ratios (Fig. 36).   
 To indirectly evaluate oxidative stress the presence of 4-hydroxy-2-nonenal (4-
HNE), a marker of lipid peroxidation was determined.  Immunofluorescent 
histochemistry using an antibody that recognizes 4-HNE showed minimal staining in 
animals on the control diet.  Ethanol-fed rats had a mild increase in the amount of 4-HNE 
staining, which was further exacerbated by the combination of ethanol and LPS.  SAMe 
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injections, however, markedly reduced the amount of 4-HNE staining suggesting that 
SAMe administration can decrease lipid peroxidation in our model of fibrosis (Fig. 37). 
SAMe inhibits ethanol-induced hepatic fibrosis. 
 Histological changes following the 8 week ethanol study were assessed by H&E 
staining of formalin-fixed tissue samples.  Sections from C and S groups demonstrated 
normal liver architecture.  Ethanol consumption alone resulted in micro- and 
macrovesicular steatosis similar to that observed from both the 7 week ethanol pilot and 
10 week ethanol study.  However, unlike previous studies semi-weekly i.p. injection of 
LPS at 0.5 mg/kg resulted in areas of focal infiltration of small cells.  Treatm nt with 
SAMe at 10 mg/kg daily abolished both the inflammation and micro- and macrovesicular 
steatosis observed in EL animals (Fig. 38). 
 To determine if hepatic fibrosis was induced by 8 weeks of ethanol administraton 
coupled with semi-weekly injections of 0.5 mg/kg LPS, Sirius red staining of formalin-
fixed sections was performed.  Minimal collagen staining was observed in control and 
animals treated with SAMe alone.  Ethanol resulted in an increase in perivenular collagen 
staining.  Treatment of ethanol-fed animals with LPS increased perivenular fibrosis and 
led to marked perisinusoidal fibrosis compared to animals fed ethanol alone.  SAMe-
administration abolished both perivenular and perisinusoidal fibrosis compared to ethanol 
and ethanol plus LPS animals (Fig. 39).  Quantitation of areas positive for collagen 
staining revealed a significant increase in collagen staining for animals fed ethanol 
compared to controls.  This was further exacerbated by the combination of LPS plus 
ethanol.  SAMe treatment, however, restored collagen staining to normal levels (Fig. 40). 
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Infiltration of PMNs and activation of HSCs is inhibited by SAMe. 
 Chronically-injured liver often results in activation of HSCs and infiltration of 
inflammatory cells, such as polymorphonuclear leukocytes (PMNs).  Animals on diets 
containing ethanol alone had mild staining for PMNs, suggesting inflammation.  This 
effect was exacerbated by the combination of ethanol plus semi-weekly LPS.  Treatment 
with SAMe diminished this effect, suggesting a decrease in inflammation (Fig. 41).   
 Animals on control diet and control plus daily SAMe injections had low levels of 
αSMA protein expression.  Ethanol consumption resulted in a significant increase in 
αSMA expression, which was further significantly increased by the combination of 
ethanol plus semi-weekly LPS injections.  Administration of SAMe restored αSMA 
protein expression to control levels (Fig. 42).   
Effects of SAMe on TGF-β signaling pathway. 
 Because numerous studies have established a link between oxidative stress and 
lipid peroxidation with an increase in the production and signaling of TGF-β [265-268], 
we examined the effects of SAMe administration on the expression of members of the 
TGF-β signaling pathway.  Animals on control diets had similar mRNA expression levels 
of TGF-β.  Chronic ethanol consumption resulted in significantly elevated TGF-β mRNA 
levels; however, ethanol coupled with semi-weekly LPS injections resulted in no further 
increase.  Treatment with SAMe significantly reduced TGF-β mRNA expression (Fig. 
43).   
 To examine the effects of SAMe on downstream TGF-β signaling components, 
mRNA expression for Smad3 and Smad7 were determined.  Animals receiving control 
diet, control diet plus SAMe, and ethanol feeding alone had similar levels of Smad3 
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mRNA expression.  LPS injections coupled with chronic ethanol feeding, however, 
resulted in a significant increase in Smad3 expression, suggesting that the combination of 
LPS and ethanol may enhance TGF-β signaling.  Treatment with SAMe resulted in a 
significant decrease in Smad3 expression compared to animals in the EL group (Fig. 43).  
Expression of the Smad3 inhibitor, Smad7, was consistent between animals receiving 
control diet and control diet plus daily SAMe injections.  Animals in the ethanol-fed 
group and ethanol-fed group plus semi-weekly LPS injections had a significant decrease 
in Smad7 expression, suggesting that ethanol feeding can also enhance TGF-β signaling 
by downregulating a key inhibitory molecule of Smad3 signaling.  This effect was 
abolished by SAMe treatment, resulting in a significant increase compared to the E and 
EL groups (Fig 43).   
BDL model of hepatic fibrosis 
Therapies to evaluate hepatic fibrosis must be evaluated to determine their 
efficacy as both a preventative treatment and curative treatment.  Because a model of 
ethanol-induced hepatic fibrosis required 8 weeks to induce mild fibrosis, we wished to 
develop a model for evaluating SAMe as a curative treatment to verify results observed in 
vitro using culture-activated HSCs.  We opted to use a bile duct-ligated model of 
experimental fibrosis using Spague-Dawley rats.  This model results in an increase of 
both type I collagen message (α1 I) procollagen mRNA) and protein production within 5 
days [29] and has been used to evaluate the efficacy of SAMe as a treatment using gross 
histological markers [237].  The molecular mechanisms of the inhibitory actions of 
SAMe were not evaluated, however.  We sought to develop a BDL model where 7 days 
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of BDL alone were followed by 7 additional days of treatment with SAMe or an equal 
volume of saline. 
Materials and Methods 
BDL model of hepatic fibrosis 
 Using male Sprague-Dawley rats between 350 and 450 g, a mid-line laparotomy 
was performed under anesthesia and the bile duct was identified, doubly-ligated with silk 
suture, and transected.  The abdominal incision was closed using absorbable suture in a 
continuous pattern and the skin closed with non-absorbable suture in an interrupted 
pattern.  Sham operations were performed in an identical manner, except without ligation
and transaction of the bile duct.  Animals were followed for 7, 14, or 21 days and 
sacrificed by exsanguination under anesthesia to collect tissue.  To test the fficacy of 
SAMe as a therapeutic for hepatic fibrosis, BDL or Sham operations were again 
performed.  Animals were allowed to recover for 7 days.  On post-operative day 7 
animals were treated daily with injections of 10 mg/kg SAMe-toluene sulfonate or an 
equal volume of saline.  On post-operative day 14 animals were sacrificed by 
exsanguination under anesthesia and tissues were collected.  Samples for histology were 
fixed for 20 hours in 10% neutral-buffered formalin, washed with tap H2O, and stored for 
processing in 70% ethanol.  Samples for protein and isolation of RNA were snap-frozen 
in liquid nitrogen.  Picro-sirius red staining, and hematoxylin and eosin (H&E) staining 
were performed by the image technician in the UNC Charlotte Department of Biol gy. 
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Results 
BDL results in hepatic fibrosis. 
 To validate the efficacy of our model to induce hepatic damage, a small pilot 
study was performed.  Animals (n=8) were subjected to either sham operation or BDL
and allowed to recuperate for 7, 14, or 21 days.  H&E staining revealed normal liver 
architecture in the sham operated animals.  BDL resulted in disruption of normal liver 
architecture in as little as 7 days with proliferation of bile duct epithelial cells around the 
portal triad and infiltration of small cells with maximum duct formation at 21 days(Fig. 
44).  Sirius red staining showed very little staining in all three zones of the sham operated 
animal, except for some collagen in the portal triad.  By day 7 there was extensive 
staining for collagen, predominantly in the portal region (zone 1).  Samples from day 14 
and day 21 showed an increase in collagen staining compared to day 7 but little apparent 
difference between the two (Fig. 45). 
SAMe attenuates liver fibrosis in BDL animals. 
 To assess SAMe as a potential reversing agent for hepatic fibrosis, we utilized the 
BDL model for fibrosis.  Animals were subjected to either sham operation or BDL.  At 
post-operative day 7, sham and BDL animals were further sub-divided into two 
additional groups, one set receiving SAMe 10 mg/kg i.p. daily and the other set receiving 
an equal volume of saline i.p. daily for an additional 7 days.  Sirius red staining revealed 
that BDL CTRL animals had significantly higher levels of type I collagen versus both 
sham groups (3.196% area vs. 0.627% and 0.629% respectively for sham CTRL and 
sham SAMe).  SAMe treatment significantly abrogated this effect (1.484% vs. 3.196%) 
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(Fig. 46).  ANOVA on the ranks was performed to determine significance (n=8 for all
groups). 
SAMe decreases procollagen and αSMA steady-state mRNA levels in BDL rats 
 To determine if SAMe altered the expression of key mediators of fibrosis 
following BDL, RT-PCR was performed to analyze steady-state mRNA levels of α1(I) 
procollagen, α2(I) procollagen, and αSMA.  BDL resulted in a significant increase in the 
levels of all three messages.  Treatment with SAMe led to a significant decreas  of 
αSMA expression compared to the BDL vehicle group.  No significant decreases were 
observed when comparing levels of α1(I) and α2(I) procollagen expression between BDL 
vehicle and BDL SAMe-treated animals (Fig. 47).  Two-way ANOVA was performed to 
determine statistical significance (n=8 for all groups). 
Expression of MMPs and their inhibitors in BDL rats. 
 The expression of MMPs and their inhibitors, TIMPs, are altered by bile duct 
ligation.  In particular, MMP-2 and TIMP-1 are strongly upregulated following BDL 
[147].  An increase in MMP-2 is hypothesized to degrade basement membrane, allowing 
infiltration of activated HSCs and inflammatory cells to areas of injury, facilitating repair.  
Sustained MMP expression, however, may contribute to injury.  Previous studies in our 
lab support a role for MMP production by HSCs treated with SAMe.  SAMe 
administration resulted in an increase in MMP-13 expression in culture-activated HSCs 
(Cross, MS Thesis, 2004), suggesting SAMe may resolve hepatic fibrosis through 
increased MMP-13 production, which has been shown to be fibrolytic.   
 To examine the effect of SAMe administration in the resolution of hepatic 
fibrosis, we utilized our BDL model.  BDL resulted in a significant increase in MMP-2 
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mRNA expression (Fig. 48).  BDL also increased MMP-13 expression; however, this was 
not a significant increase.  Treatment with SAMe attenuated MMP-2 expression but had 
no effect on MMP-13 expression.  Levels of both TIMP-1 and -2 were elevated by BDL.  
Daily injections of SAMe starting with post-operative day 7, however, failed to reduce 
expression of TIMP levels (Fig. 49). 
Discussion 
 We sought to develop an animal model of alcoholic liver fibrosis that was easy to 
conduct and mimicked the pathophysiology observed in humans.  Previous studies have 
demonstrated ethanol consumption increases translocation of LPS from the gut into the 
blood stream [260] and endotoxin levels are increased in patients with ALD [259].  
Animals have shown chronic ethanol primes the liver for greater injury when challenged 
with a single dose of LPS [269].  However, chronic ethanol consumption coupled with 
continuous exposure to LPS results in minor injury [263], possibly due to an increased 
tolerance to endotoxin.  We proposed a “two-hit” model of alcoholic liver fibrosis 
combining chronic ad libitum ethanol consumption and intermittent exposure to LPS. 
 To test our hypothesis we first established an ethanol feeding pilot.  Animals were 
subjected to 7 weeks of either the L-D ethanol liquid diet, isocaloric control diet where 
calories from ethanol were replaced with dextrin-maltose, or L-D diet plus weekly i.p. 
injection of 0.5 mg/kg or 1.0 mg/kg of LPS.  Ethanol consumption in our model 
reproduced the micro- and macrovesicular steatosis originally reported by Lieber et al. 
[33].  Ethanol consumption causes an increase in reducing equivalents through the 
oxidative generated by its metabolism and can down-regulate key regulators of lipid
metabolism in cells, such as peroxisome proliferator-activated receptor-alha (PPAR-α) 
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[270].  No inflammation was observed in the ethanol only group, also consistent with 
previous findings.  Masson’s trichrome staining revealed no collagen staining outside the 
small amounts normally found around the portal triads, central veins, and larger blood 
vessels in animals from ethanol feeding alone and their pair-fed controls.  In animals fed 
ethanol combined with weekly injections of 0.5 mg/kg or 1.0 mg/kg of LPS there was 
evidence of peri-sinusoidal accumulation of collagen, indicating fibrogenesis.   
 The study was limited by the lack of appropriate control groups.  Animals in the C 
and E groups were sacrificed at 4 weeks and the tissue shared with the laboratory of Dr. 
Mark Clemens (UNC-Charlotte, our collaborators in the study.  Future studies will 
require appropriate control groups maintained throughout the study).  Additionally, one 
animal in the E LPS 1.0 group died 2 days after the 3rd weekly i.p. LPS injection.  1.0 
mg/kg LPS is considered a sub-acute dose (LD50 for LPS is approximately 40-50 mg/kg) 
and alone would not cause mortality.  The most likely cause of death was improper 
injection technique and additional care was taken to avoid sudden movements of rats 
while receiving injections.  
 To examine the effect of longer duration of ethanol feeding coupled with an 
increased frequency of injection, we lengthened the study to 10 weeks and changed the 
injections to 1.0 mg/kg of LPS i.p. semi-weekly and added a group of animals on the 
isocaloric control diet receiving LPS injections to ensure LPS alone was not causing the 
fibrosis observed.  Treatment with SAMe chloride was also added to the study to 
determine if fibrosis could be prevented with a 10 mg/kg dose injected i.p. every other 
day.  A group of animals receiving SAMe injections on control diets was also added to 
evaluate the effects of SAMe injection alone.  SAMe chloride was chosen over the 
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toluene sulfonate form used in vitro.  We hypothesized that a chloride salt would be more 
soluable and safer in vivo than the aromatic form. 
 Histological analysis of the 10 week ethanol study revealed mirco- and 
macrovesicular steatosis, as expected.  However, the combination of longer chronic 
ethanol consumption and the increased dosage and frequency of LPS failed to resultin
fibrosis and instead there was a marked reduction in the amount of steatosis present.  This 
observation was also found in animals treated with SAMe, though to a lesser degree.  The 
improvement in steatosis due to SAMe administration may be due to its ability to act as 
an antioxidant, restore the normal redox state in the liver, an important condition for the 
normal metabolism of lipids.  The lack of steatosis observed in LPS-treated animals may 
be due to de-sensitization of LPS targets in the liver.  Chronic exposure to circulating 
LPS diminishes injury in a chronic ethanol model.  By increasing the frequency and 
dosage of LPS, the response of Kupffer cells may be diminished through the down-
regulation of CD14 and toll-like receptor 4.  Chronic LPS exposure has also been shown 
to decrease signaling through toll-like receptor 4 through an increase in suppression of 
cytokine signaling-1 (SOCS1) [271].  Longterm effects due to chronic LPS exposure may 
also in part be due to changes in hormonal production from the hypothalamus-pituitary-
adrenal axis [272].  To overcome the problem of potential LPS tolerance and to improve 
the stability of the SAMe in hopes of achieving better therapeutic event, modifications 
were made to the experimental design and the ethanol study was repeated. 
 In the third, 8 week ethanol study, animals were fed either L-D ethanol liquid diet 
or isocaloric control diet.  One subset of control animals received daily SAMe toluene-
sulfonate injections i.p.  The toluene-sulfonate form of SAMe has a larger anion 
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stabilizing the SAMe molecule than SAMe chloride, which has been shown to increase 
the stability of the compound [273].  At ambient and body temperature, SAMe rapidly 
decomposes, thus stable forms of the compound are necessary [274].  We hypothesized 
that using a more stable form coupled with an increased frequency of administration 
would provide a greater therapeutic benefit than SAMe chloride administered every oth r 
day.  To reduce the risk of tolerance to LPS, the dosage was reduced from 1.0 mg/kg to 
0.5 mg/kg i.p. semi-weekly.  Because the effects of LPS alone are well-documented in 
the literature, we omitted the control group receiving LPS injections. 
 Chronic ethanol consumption for 8 weeks again led to marked steatosis micro- 
and macrovesicular steatosis.  This was accompanied by mild infiltration of PMNs 
activation of HSCs.  Addition of semi-weekly LPS injections exacerbated the hepatic 
infiltration and resulted in greater cell damage.  Furthermore, LPS led to an increase in 
HSC activation and collagen production.  Detailed examination of histological staining 
for collagen revealed preferential pericellular localization for collagen, which is an 
indicator of advanced fibrosis.  These data suggest that our 8 week ethanol model is 
appropriate for examining the development of ALD and hepatic fibrosis.  Although the 
extensive “chicken-wire” fibrosis did not develop, future experiments can focus with 
extending the length of the ethanol feeding to see if further progression of the disease 
occurs, or if as experienced in the 10 week ethanol study, there is actually blunting of 
injury with continued LPS injection.  Although the L-D resulted in chronically elevated 
ethanol levels, the extent of intoxication was mild.  Studies utilizing ethanol-preferring 
rats may demonstrate increased injury through higher levels of circulating ethanol levels.  
Genetic approaches to overcome the natural tolerance of rats to LPS may also be
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utilizied, such as targeting SOCS1 expression.  However, care must be taken to 
specificially target SOCS1 expression in the liver to prevent systemic consequences of 
SOCS1 inhibition. 
 Treatment with daily injections of 10 mg/kg SAMe toluene-sulfonate significa tly 
ameliorated injury caused by the combination of ethanol and LPS.  There was a 
significant reduction in the amount of collagen accumulation, steatosis, and inflammation 
compared to ethanol and LPS treated animals.  This suggests that SAMe is an effective 
preventative treatment for initiation of alcoholic fibrosis.  Examination of the mechanism 
of SAMe-mediated attenuation of injury revealed a decrease in oxidative stress generated 
by the combination of ethanol and LPS.  Levels of CYP2E1 were reduced with SAMe 
administration and there was a significant reduction in the GSSG/GSH ratio and 4-HNE
accumulation, demonstrating that SAMe can act as an antioxidant in an ethanol model of 
liver fibrosis. 
 SAMe treatment also decreased the expression of a key mediator of fibrogenesis, 
TGF-β, as well as diminishing the expression of key TGF-β signaling molecules, Smad3 
and Smad7.  SAMe treatment decreased Smad3 which has been implicated in the 
transdifferentiation of HSCs as well as collegen production and organization of stress 
fibers.  The inhibitor of TGF-β signaling, Smad7, was reduced by ethanol consumption 
while SAMe treatment restored Smad7 to normal levels.  TGF-β from both HSCs and 
Kupffer cells is a key mediator of hepatic fibrosis.  Although LPS did not elevate TGF-β 
in our model of alcoholic fibrosis, LPS did alter the expression of key TGF-β signaling 
molecules, possibly potentiating the effects of TGF-β on HSCs.  Administration of SAMe 
inhibited both the production of TGF-β in the livers of ethanol-fed rats as well as 
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restoring the normal expression patterns of Smad3 and Smad7, potentially limiting the 
signaling of TGF-β in target cells such as the HSCs.  Further investigation of the 
relationship between ethanol, LPS, TGF-β, and the downstream regulators of TGF-β 
signaling should be investigated further in cultured HSCs and Kupffer cells. 
 These studies established a model for producing hepatic fibrosis from a rat odel 
of chronic ethanol consumption by the addition of semi-weekly administration of a low 
dose of LPS.  This model will provide a means for studying the initiation and progressin 
of alcoholic hepatic fibrosis as well as a platform for evaluating treatments to both 
prevent and resolve fibrosis.  Our model also has the advantages of utilizing the widely-
available Lieber-Decarli liquid ethanol diet as well as being minimally invasive.  Other 
methods to overcome the natural aversion of rodents to ethanol consumption such as the 
Tsukamoto-French intragastric ethanol infusion model are costly and require intensive 
surgical intervention and upkeep.  We also established a role for the antioxidant SAMe as 
a therapeutic treatment to prevent the development of alcoholic liver fibrosis utilizing our 
model.  These data show that SAMe can diminish oxidative stress through the restoration 
of reduced glutathione as well as inhibiting, in part, the increase in expression of 
CYP2E1, a key enzyme in the metabolism of ethanol that has been implicated in 
generating oxidative stress.  4-HNE, a marker of lipid peroxidation often associ ted with 
oxidative stress, was also diminished by SAMe.  SAMe treatment also decreased the 
expression and downstream signaling of a key fibrogenic cytokine, TGF-β.  This 
cytokine can be produced by several cell types in the liver, such as the Kupffer cell and 
HSCs.  SAMe may be exerting effects on both cell types.  Further investigation using in 
vitro cell culture may help elucidate this mechanism more clearly. 
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 To examine SAMe as a therapeutic treatment to reverse established fibrosis we 
established a BDL model of hepatic fibrosis.  BDL mimics cholestasis in humans and 
causes injury through the blocking of free bile flow, resulting in injury to hepatocyte 
membranes due to the detergent action of hydrophobic bile acids [25].  Inflammation is 
also considered a key component of cholestasis-mediated fibrosis with neutrophils, 
Kupffer cells, and lymphocytes all playing a contributing role [29]. 
 Prior to testing the effects of SAMe, we sought to validate our model based on 
previously reported findings.  BDL is reported to result in the accumulation of peri-portal 
(zone 3) collagen, proliferation of bile duct epithelium, infiltration of inflammatory cells, 
and mild biliary infarcts [29].  In comparison to the sham-operated animal, there was 
accumulation of peri-portal collagen beginning with day 7, and increased in days 14 and 
21.  H&E staining also confirmed the previously reported findings of ductular 
proliferation and small cell inflammation, with the latter most prevalent at day 7.   
 We then sought to evaluate the antioxidant SAMe as a treatment for already 
established fibrosis utilizing our BDL model.  Animals subjected to either sham or BDL 
operations were allowed to recover for 7 days.  One week BDL in our pilot as well as 
previously described in the literature is enough time to begin fibrogenesis.  On post-
operative day 7 animals received daily injections of either 10 mg/kg SAMe or an equal 
volume of saline as a vehicle.  Treatment continued for 7 days before animals were 
sacrificed and analyzed.   
 Because previous investigators have established a link between MMPs and their 
inhibitors (TIMPs), we sought to investigate the role SAMe administration may play in 
the expression levels of MMP-2, -13, TIMP-1, and -2 in a BDL model of hepatic fibrosis.  
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BDL as expected increased MMP-2 and TIMP-1 and -2.  SAMe decreased MMP-2 
expression, however, it had no influence on TIMP-1 or -2.  SAMe administration also 
had no influence on MMP-13 steady state mRNA levels.  The observation that SAMe 
decreases MMP-2 may contribute to the decrease in injury seen in BDL animals treated 
with SAMe.  MMP-2 is associated with basement membrane degredation, allowing 
migration of activated HSCs and infiltration of inflammatory cells.  By decreasing levels 
of MMP-2, SAMe might be acting to decrease inflammation to attenuate injury. 
 Although SAMe treatment of culture-activated HSCs resulted in MMP-13 
production in vitro, no change in mRNA expression was observed in animals subjected to 
BDL followed by daily treatment with SAMe.  Although this data would suggest SAMe 
does not increase expression of interstitial collagenase i  vivo, further experimentation 
should be performed.  Collagenase and gelatinase activity in vivo is regulated by the 
balance of MMP activity and expression of TIMPs.  Because MMPs have multiple 
regulatory “checkpoints” such as cleavage of the pro-MMP to the active form, 
zymographys should be performed on tissue samples to determine MMP activity.  
Combining gene expression data with measurement of MMP activity will give a more 
complete picture of the effects of SAMe on MMP expression as opposed to analysis by 
Western blot or RT-PCR. 
 Analysis through Sirius red staining revealed that BDL induces marked 
proliferation of bile duct epithelium, inflammation, and collagen deposition.  Treatment 
with SAMe significantly decreased the amount of type I collagen secretion.  SAMe 
treatment, however, did not significantly decrease the mRNA expression of α(1)I and 
α(2)I procollagens.  SAMe did, however, decrease the expression of αSMA mRNA.  
110 
 
These results seemingly pattern the results seen with SAMe treatment of culture-activated 
HSCs; a decrease in type I collagen secretion, decrease in αSMA mRNA expression, but 
no change in procollagen mRNAs.  This suggests that SAMe is a suitable treatment for 
the resolution of established fibrosis.  Furthermore, in established fibrosis SAMe may 
have similar effects on HSCs in vivo as it does on culture-activated HSCs in vitro.  
Therefore we conclude that we developed an appropriate model for examining the 
treatment with SAMe in a model of established fibrosis.  These results may also be 
appropriate with drawing parallels with observations noted in treating culture-activated 
HSCs with SAMe. 
 Future studies to isolate HSCs from our ethanol model of hepatic fibrosis will 
allow us to characterize the in vivo mechanism of SAMe, allowing us to make 
comparisons to in vitro observations. Our ethanol model will also permit the evaluation of 
other candidate treatments for fibrosis, as well as further investigation the progr ssion of 
disease. 
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Figure 22.  Weekly weights of animals on the 7 week ethanol pilot study.  Animals were 
permitted ad libitum access to the Lieber-DeCarli liquid ethanol diet (E) with 36% of the 
total calories provided by ethanol. Control animals (C) received an isocaloric diet where 
calories from ethanol were replaced by dextrin-maltose.  Two subsets of animals on the 
ethanol diet received either 0.5 mg/kg LPS i.p. weekly (EL 0.5) or 1.0 mg/kg LPS i.p. 
weekly (EL 1.0).  Animals were weighed weekly throughout the study. 
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Figure 23.  Weight change for animals on the 7 week ethanol pilot study.  To compare 
weight change of animals in the study, the difference in weights from initiation of the 
study to its conclusion were determined.  Animals were permitted ad libitum access to the 
Lieber-DeCarli liquid ethanol diet (E) with 36% of the total calories provided by ethanol. 
Control animals (C) received an isocaloric diet where calories from ethanol were replaced 
by dextrin-maltose.  Two subsets of animals on the ethanol diet received either 0.5 mg/kg 
LPS i.p. weekly (EL 0.5) or 1.0 mg/kg LPS i.p. weekly (EL 1.0). 
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Figure 24.  Ethanol liquid diet plus LPS induces early fibrosis.  Formalin-fixed samples 
were embedded in paraffin and sectioned.  Masson’s trichrome staining was performed 
on slides and 10X micrographs taken.  Sections from control (C) and ethanol (E) animals 
showed minimal type I collagen deposition.  Treatment of ethanol-fed rats with either 0.5 
(EL 0.5) or 1.0 (EL 1.0) mg/kg LPS resulted in a mild fibrosis. 
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Figure 25.  Early fibrosis in animals fed in conjunction with LPS injections occurs peri-
sinusoidally.  Formalin-fixed samples were embedded in paraffin and sectioned.  
Masson’s trichrome staining collagen was performed on slides and 20X micrographs 
taken.  Large size image is presented to better display peri-sinusoidal collagen staining 
(arrows) from an animal fed ethanol in conjunction with weekly LPS injections. 
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Figure 26.  Weekly animal weights from the 10 week ethanol study.  Animals were 
permitted ad libitum access to the Lieber-DeCarli liquid ethanol diet (E) with 36% of the 
total calories provided by ethanol. Control animals (C) received an isocaloric diet where 
calories from ethanol were replaced by dextrin-maltose.  Two subsets of animals on the 
control diet received either 1.0 mg/kg LPS i.p. semi-weekly (L) or 10.0 mg/kg SAMe 
chloride i.p. every other day (S).  Two subsets of animals on the ethanol diet received 
either 1.0 mg/kg LPS i.p. semi-weekly (EL) or 1.0 mg/kg LPS i.p. semi-weekly and 10.0 
mg/kg SAMe chloride i.p. every other day (ELS).  Animals were weighed weekly 
throughout the study. 
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Figure 27.  Weight change for animals on the 10 week ethanol study.  To compare weight 
change of animals in the study, the difference in weights from initiation of the study to its 
conclusion were determined.  Animals were permitted ad libitum access to the Lieber-
DeCarli liquid ethanol diet (E) with 36% of the total calories provided by ethanol. 
Control animals (C) received an isocaloric diet where calories from ethanol were replaced 
by dextrin-maltose.  Two subsets of animals on the control diet received either 1.0 mg/kg 
LPS i.p. semi-weekly (L) or 10.0 mg/kg SAMe chloride i.p. every other day (S).  Two 
subsets of animals on the ethanol diet received either 1.0 mg/kg LPS i.p. semi-weekly 
(EL) or 1.0 mg/kg LPS i.p. semi-weekly and 10.0 mg/kg SAMe chloride i.p. every other 
day (ELS). 
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Figure 28.  Ethanol results in micro- and macrovesicular steatosis.  Formalin-fixed 
samples were embedded in paraffin and sectioned.  H&E staining was performed n 
slides and 10X micrographs taken.  Micro- (narrow arrow) and macrovesicular steatosis 
(bold arrow) were seen in animals receiving ethanol (E) alone.  No inflammation was 
observed in any group and normal liver architecture was preserved. 
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Figure 29.  Ethanol and LPS does not lead to hepatic fibrosis. Formalin-fixed samples 
from 10 week ethanol study animals were embedded in paraffin and sectioned.  Sirius red 
staining for collagen was performed on slides and 10X micrographs taken.  No collagen 
staining was observed in any group, except vessel-associated collagen normally found 
around portal triads and central veins. 
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Figure 30.  Animal weights for the 8 week ethanol study.  Animals were permitted ad 
libitum access to the Lieber-DeCarli liquid ethanol diet (E) with 36% of the total calories 
provided by ethanol. Control animals (C) received an isocaloric diet where calo ies from 
ethanol were replaced by dextrin-maltose.  One subset of animals on the control diet 
received 10.0 mg/kg SAMe toluene-sulfonate i.p. daily (S).  Two subsets of animals on 
the ethanol diet received either 0.5 mg/kg LPS i.p. semi-weekly (EL) or 0.5 mg/kg LPS 
i.p. semi-weekly and 10.0 mg/kg SAMe toluene-sulfonate i.p. daily (ELS).  Animals were 
weighed weekly throughout the study. 
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Figure 31.  Animal weight change during 8 week ethanol study.  Weight change 
comparison for each animal group in the study.  Animals were permitted ad libitum 
access to the Lieber-DeCarli liquid ethanol diet (E) with 36% of the total calories 
provided by ethanol. Control animals (C) received an isocaloric diet where calo ies from 
ethanol were replaced by dextrin-maltose.  One subset of animals on the control diet 
received 10.0 mg/kg SAMe toluene-sulfonate i.p. daily (S).  Two subsets of animals on 
the ethanol diet received either 0.5 mg/kg LPS i.p. semi-weekly (EL) or 0.5 mg/kg LPS 
i.p. semi-weekly and 10.0 mg/kg SAMe toluene-sulfonate i.p. daily (ELS).  Animals were 
weighed weekly throughout the study. 
 
 
 
 
 
 
 
 
 
 
0
50
100
150
200
250
C S E EL ELS
* P < 0.05 vs. S
# P < 0.05 vs. S
* #
W
e
ig
h
t c
h
a
n
g
e
 (
g
)
121 
 
 
Figure 32.  Serum ethanol concentrations from 8 week ethanol study.  Animals on control 
(C) and a subset of control animals receiving 10 mg/kg SAMe injections daily had 
undetectable levels of ethanol.  Animals on diets containing ethanol alone (E), ethanol 
plus LPS injected semi-weekly (EL), and animals fed ethanol in combination with semi-
weekly LPS injections and daily SAMe injections (ELS) all had detectable levels of 
serum ethanol.  (Karaa and Thompson et al. 2008) 
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Figure 33.  Liver:body weight ratio from 8 week ethanol study.  Animals fed control diets 
(C) or control diets coupled with daily injections of SAMe had similar liver:body weight 
ratios.  Animals receiving ethanol alone (E) had significantly higher liver:body weight 
ratios.  Animals receiving ethanol and semi-weekly LPS injections (EL) as well as the 
combination of ethanol, semi-weekly LPS, and daily SAMe (ELS) had elevated 
liver:body weight ratios; however, these were not significantly increased.  (Karaa and 
Thompson et al. 2008) 
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Figure 34.  SAMe decreases cellular injury in an animal model of alcoholic liver fibrosis.  
Plasma was collected and assayed for ALT, a marker of liver injury.  Control aimals  
(C, S) had normal levels of ALT.  Ethanol administration (E) significantly increased liver 
injury, which was further increased with semi-weekly LPS injection (EL).  SAMe 
treatment reduced cellular injury to normal levels (ELS).  (Karaa and Thompson et al. 
2008) 
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Figure 35. Expression of key enzymes involved in the metabolism of ethanol.  Protein 
expression of CYP2E1, ADH, and ALDH were determined from whole liver.  Ethanol 
significantly increased CYP2E1 in the livers of ethanol-fed (E) and ethanol-fed plus 
semi-weekly LPS (EL) compared to control animals (C) and animals receiving control 
diets plus SAMe (S).  SAMe administration (ELS) significantly decreased CYP2E1 
expression.  Levels of ADH were unchanged across all groups.  ALDH levels were 
significantly increased in E and EL.  SAMe decreased ALDH compared to E and EL, but 
this was not significant.  (Karaa and Thompson et al. 2008) 
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Figure 36. GSSG/GSH is reduced with SAMe administration.  The ratio of oxidized 
glutathione (GSSG) to reduced glutathione (GSH) was determined from whole livers.  
Control animals and control animals treated with SAMe (C, S) had low GSSG/GSH 
ratios.  Ethanol feeding (E) increased this ratio, with a further increase due to semi-
weekly LPS injections (EL).  Treatment with daily SAMe (ELS) significantly reduced the 
GSSG/GSH ratio.  (Karaa and Thompson et al. 2008) 
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Figure 37.  SAMe decreases lipid peroxidation in an alcoholic model of fibrosis.  
Formalin-fixed samples were embedded in paraffin and sectioned.  Anti-4-HNE staining 
(green) was performed on slides and 20X micrographs taken.  Minimal staining for  
4-HNE was observed with animals on control diet (C) and control diet with daily 
injection of 10 mg/kg SAMe (S).  Ethanol (E) feeding resulted in a mild increase in 4-
HNE staining, which was further increased by semi-weekly LPS administration (EL).  
Treatment with SAMe (ELS) attenuated this effect.  DAPI (blue) was used to 
counterstain nuclei.  (Karaa and Thompson et al. 2008) 
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Figure 38.  SAMe restores normal histology in animals treated with ethanol and LPS.  
Formalin-fixed samples were embedded in paraffin and sectioned.  H&E staining was 
performed on slides and 20X micrographs taken.  Normal histology was observed with 
animals on control diet (C) and control diet with daily injection of 10 mg/kg SAMe (S).  
Micro- (black thin arrow) and macrovesicular (black bold arrow) steatosis wa seen in 
animals receiving ethanol alone (E).  Steatosis was reduced in animals on ethanol diets 
receiving LPS injections (EL), however, areas of focal infiltration of small cells (white 
arrow) were observed.  SAMe administration reversed both steatosis and inflammation in 
animals receiving ethanol and LPS injections (ELS). 
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Figure 39.  8 week ethanol liquid diet plus LPS induces fibrosis.  Formalin-fixed samples 
from 8 week ethanol study animals were embedded in paraffin and sectioned.  Sirius red 
staining for collagen was performed on slides and 20X micrographs taken.  Animals from 
control (C) and control plus SAMe (S) showed minimal collagen staining.  Ethanol 
feeding (E) resulted in an increase in perivenular collagen.  Semi-weekly injectio s of 0.5 
mg/kg LPS (EL) led to perisinusoidal collagen staining as well as increased perivenualar 
collagen.  Treatment with 10 mg/kg of SAMe (ELS) daily inhibited this effect. (Karaa 
and Thompson et al. 2008) 
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Figure 40.  SAMe attenuates collagen deposition in ethanol fed animals challenged with 
LPS.  Collagen content was quantitated by Sirius red staining.  Control (C) animals and 
control animals injected with SAMe (S) showed low collagen staining.  Ethanol treatment 
(E) resulted in a significant increase in perivenular collagen staining; however, LPS 
administration did result in an increase (EL).  SAMe administration significantly 
diminished collagen staining (ELS).  Analysis of perisinusoidal collagen staining 
revealed similar levels across all groups except LPS-treated animals.  This increase was 
again abolished by SAMe.  (Karaa and Thompson et al. 2008) 
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Figure 41.  SAMe decreases polymorphonuclear cell infiltration in an ethanol model of 
hepatic fibrosis.  Formalin-fixed samples were embedded in paraffin and sectioned.  Anti-
PMN staining (green) was performed on slides and 20X micrographs taken.  Minimal 
infiltration of PMN was observed with animals on control diet (C) and control diet with 
daily injection of 10 mg/kg SAMe (S).  Ethanol (E) feeding resulted in extensive 
perivenual and intrasinusoidal infiltration, which was increased by semi-weekly LPS 
administration (EL).  Treatment with SAMe (ELS) abolished this effect.  DAPI (blue) 
was used to counterstain nuclei.  (Karaa and Thompson et al. 2008) 
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Figure 42. Effect of SAMe on activation of HSCs in livers from an animal model of 
alcoholic liver fibrosis.  Whole tissue was analyzed by Western blot to determine αSMA 
expression as a marker for activation of HSCs.  Ethanol feeding resulted in a signficant 
activation of HSCs (E), which was enhanced by treatment with LPS (EL).  SAMe 
administration abrogated this effect (ELS).  (Karaa and Thompson et al. 2008) 
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Figure 43. TGF-β signaling in an ethanol model of fibrosis.  mRNA expression of 
members of the TGF-β signaling pathway in whole liver.  Ethanol treatment alone (E) 
and combined with LPS injections (EL) resulted in a significant increase in TGF-β 
expression compared to control animals (C) and control animals receiving SAMe 
injections (S).  Treatment with SAMe (ELS) significantly reduced the expression of 
TGF-β in animals fed ethanol with semi-weekly injections of LPS.  Smad3 expression 
was unchanged in C, S, and E animals, however was elevated in EL animals.  This effect 
was significantly inhibited by SAMe (ELS) treatment.  Smad7 expression was 
significantly decreased in E and EL animals, however, SAMe treatment (ELS)restored 
Smad7 expression.  (Karaa and Thompson et al. 2008) 
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Figure 44.  BDL induces liver damage and disrupts the normal hepatic architecture. 
Formalin-fixed samples were embedded in paraffin and sectioned.  H&E staining was 
performed on slides and 10X micrographs taken.  Sham sections showed normal 
architecture and no inflammation.  Sections from BDL animals showed infiltration of 
small cells near portal triads (all time points, wide arrows) and proliferation of bile duct 
epithelium (predominantly at days 14 and 21).  Areas of focal necrosis were also sen (all 
time points, narrow areas). 
 
 
 
134 
 
 
Figure 45.  BDL increases type I collagen.  Formalin-fixed samples were embedded in 
paraffin and sectioned.  Sirius red staining was performed on slides and 10X micrographs 
taken.  Sham sections showed minimal type I collagen deposition.  Sections from BDL 
animals showed fibrosis beginning at day 7 and continuing at days 14 and 21.  The 
majority of type I collagen accumulation occurred in zone 1 near proliferating bile duct 
epithelium.  Some branching fibrosis appeared to occur at day 21.    
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Figure 46.  SAMe attenuates hepatic fibrosis in BDL rats.  Sham or BDL surgery was 
performed on male Sprague-Dawley rats.  At post-operative day 7 animals were treated
either with vehicle (CTRL) or 10 mg/kg SAMe daily for 7 days.  Sirius red staining was 
performed to quantitate type I collagen accumulation.   
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Figure 47.  SAMe decreases procollagen and αSMA mRNA expression in BDL rats.  RT-
PCR on total RNA reversed transcribed from whole liver revealed a significant increase 
in the messages of α(1)I and α(2)I procollagen mRNAs, and αSMA in animals subjected 
to BDL with vehicle treatment.  Administration of daily SAMe starting on post-operativ  
day 7 of BDL animals (BDLS) resulted in a significant decrease in αSMA levels, but not 
α(1)I or α(2)I procollagen mRNA.  Sham vehicle (SV), Sham SAMe (SS), BDL vehicle 
(BDLV). 
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Figure 48.  Two week BDL increases MMP-2 expression.  RNA reversed transcribed 
from whole liver revealed a significant increase in the message of MMP-2 in animals 
subjected to BDL with vehicle treatment.  Administration of daily SAMe starting on post-
operative day 7 of BDL animals diminished this effect.  Levels of MMP-13 were
increased by BDL, however, this increase was not significant. 
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Figure 49.  TIMP expression is increased by BDL.  RT-PCR on total RNA reversed 
transcribed from whole liver showed a significant increase in the messages of TIMP-1 
and TIMP-2 in animals subjected to BDL with vehicle treatment.  Administration of daily 
SAMe starting on post-operative day 7 of BDL animals attenuated TIMP-1 and TIMP-2 
expression, but not significantly. 
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CHAPTER 5: SUMMARY AND FUTURE DIRECTIONS 
 
 
 In the normal liver, hepatic stellate cells (HSCs) are quiescent and reside in the 
space of Disse.  Quiescent HSCs store vitamin A in the form of retinyl esters [18], 
maintain the basement membrane, and regulate sinusoidal diameter through their 
cytoplasmic projections and contractile properties [41].  Upon a noxious stimulus, HSCs 
activate to a myofibroblast-like cell capable of proliferating extensively, migrating to 
areas of injury, producing proinflammatory cytokines, and secreting extracellul r matrix 
(ECM) products to facilitate healing [6].  Withdrawl of the stimulus results in a reduction 
of activated HSCs, either by apoptosis or reversion back to a quiescent phenotype.  
However, chronic injury results in the accumulation of ECM components, including type 
I collagen, disrupting the normal liver architecture resulting in impairment of utrient 
delivery and further injury leading to fibrosis.  Unresolved hepatic fibrosis can progress 
to cirrhosis, which is an end-stage liver disease with considerable morbidity and 
mortality.  Removal or treatment of the underlying cause of liver fibrosis can lead to 
spontaneous recovery [9-12]; however, in the case of alcoholic liver disease (ALD) 
recovery is hampered by continued ethanol abuse.  Thus therapies that can treat hepatic 
fibrosis in the setting of continued fibrogenic stimuli are attractive. 
 The antioxidant S-adenosyl-L-methionine (SAMe) has received attention as a 
candidate therapy for alcoholic fibrosis.  SAMe is a precursor to the intracellul r 
principal intracellular antioxidant glutathione and may prevent fibrosis through a 
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reduction in reactive oxygen species (ROS) generated through ethanol metabolism, injury 
to hepatocytes, and activation of Kupffer cells.  Previous studies have shown SAMe can 
attenuate liver injury in experimental models of hepatic fibrosis [210, 237, 275] and is 
well tolerated in human trials [209].  Although the effects of SAMe have been 
investigated in vitro utilizing HSCs, these studies focused on early-activated HSCs, 
which may be more consistent with investigating SAMe as a preventative agent.  
Culturing primary HSCs on plastic results in the spontaneous activation of HSCs from a
quiescent to myofibroblast-like phenotype and is considered the best model for 
mimicking the phenotype of HSCs in the fibrotic liver.  Therefore, we took a mechanistic 
approach to determine the effects of SAMe on culture-activated HSCs. 
 Treatment of culture-activated HSCs with increasing doses of SAMe resulted in a 
decrease in intracellular type I collagen protein expression over time; howver, this 
attenuation was not significant.  Since hepatic fibrosis is defined by the accumulation of 
ECM products, we examined the effects of a single concentration of SAMe on type I 
collagen secretion in culture-activated HSCs.  SAMe resulted in a highly significant (P < 
0.001) decrease in the amount of type I collagen secreted into culture media.  These 
results suggest SAMe may be useful in resolving hepatic fibrosis in a setting of sustained 
insult, such as chronic ethanol abuse in humans.  Our findings also demonstrated that 
SAMe-mediated type I collagen inhibition in Rat-1 fibroblasts requires NF-κB activity.  
Because of the difficulty in inhibiting NF-κB activity in culture-activated HSCs, the 
precise role of NF-κB in mediating SAMe-induced type I collagen inhibition will be 
difficult to examine.  Future experiments utilizing HSCs isolated from the livers of 
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fibrotic animals treated with SAMe will help determine if the observation that SAMe 
increases NF-κB also occurs in vivo.  
 Although treatment of culture-activated HSCs with SAMe failed to diminish 
steady-state mRNA levels of procollagen gene products as hypothesized, SAMe 
treatment resulted in the polyubiquitination of intracellular type I collagen.  This finding 
led us to investigate ER proteins to determine if SAMe administration could modulate 
their expression, potentially suggesting a role for ER stress in the mechanism of SAMe-
mediated type I collagen inhibition.  Our data showed SAMe treatment resulted in a 
significant decrease at 24 hours in the expression of protein disulfide isomerase (PDI) 
and the 78-kDa glucose-regulated protein (Grp78).  SAMe has been shown to increase 
levels of glutathione both in vitro and in vivo.  The redox status of the ER is important for 
its proper function.  High levels of glutathione may suppress the oxidizing activity of 
PDI, limiting disulfide bond formation [256, 257].  These findings may suggest a novel 
mechanism for type I collagen inhibition in activated HSCs through the selective 
retention of secretory proteins requiring precise disulfide-bond formation for proper 
assembly.  Further studies utilizing SAMe and other agents capable of producing a more 
reducing environment in the ER should be conducted to more precisely examine a 
connection between redox status changes and inhibition of type I collagen secretion in 
activated HSCs.    
Additionally, the role of polyubiquitination of type I collagen should be further 
examined in vivo.  Although SAMe-treatment failed to demonstrate co-localization of 
type I collagen and polyubiquitin, these findings are not conclusive.    Varying the time 
points at which animals are analyzed following the initiation of SAMe administration will 
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give a more accurate assessment, as the kinetics of SAMe-induced increases in typ  I 
collagen polyubiquitination were not uniform.  Furthermore, because HSCs represent 
only 15% of the liver’s cellular population, analysis of HSCs directly either throug in 
situ isolation or laser capture dissection microscopy may provide more definitive results 
than analysis of whole liver tissue. 
The second aim of this dissertation was the development of experimental models 
of hepatic fibrosis.  These models will allow us to evaluate treatments of hepatic fibrosis 
as well as better our understanding of disease progression.  Bile duct ligation (BDL) is a 
well established model of hepatic fibrosis.  To determine if we could reproduce the 
phenotype observed in BDL, as well as evaluate if SAMe could attenuate already-
established fibrosis, we subjected animals to either sham or BDL surgery, followed by 7 
days of recovery.  On post-operative day 7, animals were treated with either 10 mg/kg of 
SAMe or a saline vehicle daily for an additional 7 days.  As expected, BDL resulted in an 
increase in collagen production, as demonstrated by Sirius red staining.  SAMe 
administration decreased type I collagen expression at the protein level; how ver, there 
was not a significant decrease in either α1(I) or α2(I) procollagen mRNA levels.  SAMe 
treatment did decrease αSMA expression, suggesting either a reduction in the number of 
activated HSCs or a reversion of HSCs to a quiescent phenotype in the livers of BDL 
animals.   
Because there was a reduction in type I collagen at the protein level, but not 
mRNA level, we investigated the expression of matrix metalloproteinases (MMPs) and 
their inhibitors, tissue inhibitors of metalloproteinases (TIMPs) in our BDL model of 
hepatic fibrosis.  BDL resulted in a significant increase in profibrotic MMP-2, TIMP-1, 
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and TIMP-2 and no significant change in fibrolytic MMP-13 expression.  SAMe 
treatment attenuated MMP-2 expression in BDL animals, but the difference was not 
significantly lower than MMP-2 expression in BDL animals treated with vehicl  alone.  
Although these findings do not support a major role for SAMe in the modulation of 
MMPs and their inhibitors, TIMPs, further investigation examining the activity level of 
the respective MMPs should be conducted.  MMPs have multiple steps of regulation, 
including mRNA expression, cleavage of the pro-MMP to form the active MMP, and an 
inverse relationship between TIMP expression and MMP activity.  Studies utilizing 
zymographies should be conducted on samples from SAMe-treated animals subjected to 
BDL to better ascertain the role SAMe plays in their expression and activity. 
We also sought to develop an ethanol model of hepatic fibrosis.  Current models 
of alcoholic fibrosis suffer from a combination of difficulty in administration and a lack 
of relevance to the clinical progression of disease in humans.  To develop a “two-hit” 
model of alcoholic fibrosis, we administered lipopolysaccharide (LPS) injections 
concurrently with chronic ethanol feeding utilizing the Lieber-DeCarli (LD) liquid 
ethanol diet.  LPS was chosen based on observations that ethanol consumption increases 
the permeability of the gut to endotoxin [276] and an increase in plasma endotoxin in 
patients with ALD as well as following acute ethanol consumption [259]. 
The initial pilot study comprised of daily ethanol consumption and weekly 
injections of either 0.5 mg/kg or 1.0 mg/kg LPS resulted in the formation of mild fibrosis.  
To evaluate if increasing both the frequency of LPS injection and duration of the study 
resulted in greater fibrosis, the study was repeated using semi-weekly injctio s of 1.0 
mg/kg LPS in conjunction with 10 weeks of ethanol feeding.  This model failed to 
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demonstrate hepatic fibrosis.  We hypothesized that the combination of increased LPS 
dosage coupled with an increase in the frequency of administration may have induced 
tolerance to LPS in the liver, blunting its effects.  This is supported by findings that 
continuous LPS infusion diminishes injury in a model of chronic ethanol feeding [263]. 
We then modified our hypothesis to semi-weekly low-dosage (0.5 mg/kg) LPS 
injections in animals on the LD diet would produce hepatic fibrosis.  Following 8 weeks 
of feeding and injections of LPS, animals were evaluated for hepatic fibrosis.  Ethanol 
feeding alone resulted in increased activated HSCs and perivenular collagen production.  
Treatment with LPS increased both these measures of hepatic fibrosis.  In particular, 
ethanol plus LPS resulted in a highly significant increase in perisinusoidal collagen 
staining.  Fibrosis was associated with increased inflammation, a higher ratio of oxidized 
glutathione (GSSG) to reduced glutathione (GSH), and increased expression of mediators 
of transforming growth factor-beta (TGF-β) signaling.   
To evaluate if SAMe administration concomitantly with ethanol consumption and 
LPS injections would inhibit hepatic fibrosis, animals were injected daily with 10 mg/kg 
SAMe.   Treatment with SAMe significantly decreased markers of hepatic fibrosis, 
including collagen staining, αSMA expression, and inflammation.  SAMe also restored 
the normal ratio of GSSG/GSH, suggesting a decrease in oxidative stress.  Finally, SAMe 
decreased TGF-β expression, and expression of a key downstream signaling molecule of 
TGF-β, Smad3.   
These findings demonstrate that the combination of chronic ethanol consumption 
utilizing the LD diet coupled with semi-weekly injections of LPS can produce hepatic 
fibrosis within 8 weeks.  This “two-hit” model of alcoholic liver fibrosis provides a 
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simple and easily administered model to evaluate the development and prevention of 
hepatic fibrosis.  Although this model did not result in extensive “chicken-wire” fibrosis 
that links adjacent lobules in the liver, future experiments focusing on increasing the 
duration of ethanol feeding with LPS injections can evaluate the extent of fibrosis that 
can be generated.  We also demonstrated that our model can be modulated with 
administration of the antioxidant, SAMe.  This suggests our model can be used as a 
platform to prevent the onset of hepatic fibrosis in a “two-hit” model.  Future studie to 
evaluate the efficacy of other treatments both alone and in comparison with more 
established treatments such as SAMe will allow us to increase the pool of candidate anti-
fibrotic agents.  Finally, studies utilizing this model can be used to examine the role of 
SAMe in the reversal of already-established alcoholic fibrosis. 
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